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Coronary heart disease, especially myocardial infarction, is a serious and deadly 
disease that remains the number one cause of death in developed nations.  While 
physicians have a wide array of drugs and tools at their disposal to treat myocardial 
infarction, there is a scarcity of drugs that effectively prevent the pathological remodeling 
of the left ventricle that occurs after acute infarction and greatly predisposes the patient to 
the risk of heart failure. 
This dissertation focuses on identifying nonviral, bioreducible polymer-based 
gene therapies to limit infarct expansion, prevent left ventricular remodeling, and retain 
heart function after myocardial infarction. Bioreducible polymers represent a major 
advancement in nonviral technology to transfect primary cells, with high efficiency, and 
low cytotoxicity. 
We first examined a combined gene/cell therapy-based strategy by implanting 
VEGF165-transfected primary skeletal myoblasts to the myocardium of infarcted rat hearts. 
The VEGF-expressing skeletal myoblasts acted as bioreactors, secreting proangiogenic 
VEGF and inducing new vessel formation in the infarcted hearts. This treatment strategy 
produced both global and regional improvements in the left ventricle, improving ejection 
fraction, decreasing cell death, and limiting left ventricular remodeling. 
A cationic polymer system utilizing arginine-grafted bioreducible polymer (ABP) 
was also used to efficiently mediate siRNA knockdown of BNIP3, a hypoxia-inducible 
iv 
proapoptotic protein. siRNA-mediated BNIP3 knockdown both in vitro and in vivo 
protected rat primary cardiomyocytes from hypoxic death. The inhibition of BNIP3 in 
acutely ischemic rat hearts resulted in improved retention of ejection fraction, decreased 
infarct formation, decreased cellular remodeling, and decreased left ventricular 
remodeling. 
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1.1 General Introduction 
Gene therapy is broadly defined as the use of nucleic acids as pharmacological 
agents at a cellular level to correct genetic abnormalities and dysfunction or to express a 
protein to treat a disease. Over the past 40 years, the concept of treating or curing disease 
at its genetic root has moved from mere speculation to a more immediate reality, with 
thousands of gene therapy clinical trials performed to date [1, 2]. Gene therapy can take 
many forms, whether it is used to deliver plasmid DNA, small interfering RNA (siRNA), 
or sense/antisense oligonucleotides and these techniques have all been used in clinical 
therapies to treat diseases such as muscular dystrophy, cancer, cardiovascular disease, 
and even HIV [3-6]. 
However, despite the promise of gene therapy and our increased understanding of 
the genetic abnormalities that cause disease, the greatest barrier to achieving efficient 
gene therapy remains the delivery of genetic material to the population of diseased cells 
[7, 8]. The earliest attempts to overcome the cellular barrier to gene therapy in humans 
utilized crude and inefficient calcium phosphate systems to chemically transfect bone 
marrow cells and reinfuse them into the patients [9-11]. More efficient viral systems were 
not used for gene therapy until several years later and while they are still the predominant 
vectors used for gene therapy trials today [2], they are not without significant problems 
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such as immunogenicity, mutagenic potential, toxicity, high expense, and difficulty in 
manufacture [12, 13]. 
Nonviral vectors for gene therapy represent a promising alternative to viral 
vectors for gene delivery as they do not suffer from many of the same limitations [14, 
15]. Polymer gene carriers are especially attractive as nonviral vectors because they 
efficiently protect nucleic acids from degradation, mediate transport across cell 
membranes, and can be easily modified with shielding agents like polyethylene glycol to 
increase circulation time and decrease toxicity, or modified with targeting motifs to 
imbue cell-type specificity to the polymer complex [16, 17]. 
The work in this dissertation evaluated the application of polymer gene delivery 
to treat the deleterious effects of pathological left ventricular remodeling after myocardial 
infarction. Myocardial infarction (MI) is a pathological state characterized by an acute 
loss of blood supply to the myocardium due to coronary artery occlusion. The obstruction 
results in decreased oxygen and nutrient delivery to myocardial tissues, causing local 
tissue death and formation of an infarct. This tissue loss occurs via necrosis, apoptosis, 
and autophagy and results in a weaker heart that is greatly predisposed to cardiac failure. 
Significant interest has been shown in developing therapeutic interventions to limit 
remodeling of the left ventricle (LV), restore heart function, and improve long-term 
patient prognosis, as the current pharmacological treatments do little to prevent LV 
remodeling. One technique that has shown potential is antiapoptotic and proangiogenic 
gene therapy of the LV to restore heart function and limit infarct expansion. While most 
gene therapy research for treating MI has focused on delivery of recovery factors to 
ameliorate damage to the myocardium [18-20], current research has suggested that there 
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are some very promising targets that can help cardiomyocytes survive the hypoxic insult 
caused by MI, such as targeting proapoptotic factors like BNIP3, a hypoxia-inducible cell 
death switch that has been shown to be highly upregulated in the myocardium 
post-MI [21-23]. 
The work in this dissertation focuses on two therapeutic approaches applying 
polymer-mediated gene delivery to treat myocardial infarction and tests these approaches 
in animal models. First, we detail a combined cell therapy/angiogenic strategy where 
primary rat skeletal myoblasts were transfected ex vivo with a VEGF165 plasmid and then 
implanted directly to the infarcted rat myocardium to act as VEGF bioreactors. Second, 
we detail the design of small interfering RNA (siRNA) towards BNIP3, a proapoptotic 
protein specifically upregulated by hypoxia and the validation of this target to ameliorate 
hypoxic cell death after exposure to hypoxia. This in vitro validation was then further 
investigated in a rat model of myocardial ischemia/reperfusion injury. 
The multiple approaches to ameliorating the deleterious effects of left ventricle 
remodeling postmyocardial infarction in this study lead to the dual hypothesis that 1) 
implantation of VEGF165-expressing skeletal myoblasts to infarcted myocardium 
preserves heart function, increases neoangiogenesis, decreases cardiomyocyte cell death, 
and increases cardiomyocyte viability, and that 2) reduction of cardiomyocyte BNIP3 
levels after myocardial infarction in the short term by siRNA therapy results in decreased 
hypoxia-induced cell death, increased cell survival, and retention of heart function.  
1.2 Study Rationale 
The work in this dissertation focuses on identifying polymers with high 
biocompatibility and low toxicity, identifying and validating gene targets for the 
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treatment of myocardial infarction, and combining the two components together to 
successfully treat and limit the negative effects of left ventricular remodeling in animal 
models of myocardial infarction (Figure 1.1). 
The chapter following this brief introduction contains background information 
and a review of the current literature surrounding myocardial infarction, siRNA and 
plasmid gene therapy for cardiovascular disease, and polymer gene carriers. 
The work in Chapter 3 is unique as it combines polymer-mediated gene therapy 
with cell therapy to revascularize and repopulate the myocardium after myocardial 
infarction. This chapter details the ex vivo transfection of primary rat skeletal myoblasts 
with a gene expressing VEGF165 and the implantation of these cells in the cardiac wall 
post-MI. Most angiogenic gene therapy approaches have focused on direct transfection of 
the endogenous myocardial cell population of cardiomyocytes and fibroblasts. However, 
these cell populations have proven to be extremely difficult to transfect in situ, which 
results in low expression of transgenes. By transfecting skeletal myoblasts ex vivo with an 
efficient and nontoxic bioreducible polymer, we were able to attain high transfection 
efficiency, combining the benefit of high angiogenic factor expression and secretion to 
surrounding tissues with the positive benefit of cell therapy with a myocyte progenitor 
cell. The implanted cells provide further benefit by repopulating the myocardium and by 
secreting recovery factors into the myocardial milieu. 
The fourth chapter describes the work that was done in determining the polymer 
gene carriers that would be used in later studies to directly transfect the myocardium with 
high efficiency and low toxicity. This chapter also details the work performed to evaluate 





Figure 1.1. Graphical overview of myocardial infarction therapy strategies. 
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myocardium. An in vitro model of hypoxia was used to determine the effects of BNIP3 
knockdown on hypoxia survival. To increase the translatability to subsequent in vivo 
studies, primary rat neonatal cardiomyocytes were used. 
Chapter 5 applies the work performed in the previous chapter in an in vivo rat 
model of ischemia/reperfusion injury. The transient knockdown of BNIP3 immediately 
after ischemia/reperfusion injury was achieved by delivering BNIP3 siRNA directly to 
the myocardium with a novel arginine-conjugated bioreducible polymer. Direct 
myocardial siRNA gene therapy is easier to achieve than myocardial plasmid gene 
therapy as siRNA needs only reach the cytoplasm to exert its action, whereas plasmids 
must penetrate the nucleus in order for expression to occur. 
1.3 Specific Aims 
In order to test the aforementioned hypotheses, this dissertation was broken up 
into three separate specific aims. 
1.3.1 Specific Aim 1 
Determine if intramyocardial implantation of VEGF165-transfected skeletal 
myoblasts after acute myocardial infarction in rats results in retained heart function, 
decreased infarct size, increased cardiomyocyte viability, and increased capillary and 
arteriole formation. 
We used a rat model of permanent coronary artery occlusion and randomly 
assigned animals to one of four groups: 1) sham operation control (thoracotomy only), 2) 
ligation only, 3) implanted skeletal myoblasts alone, and 4) implanted VEGF165-
expressing skeletal myoblasts. Cardiac function and ventricle geometry were measured 
four-weeks after surgery by MRI. Histology to determine infarct size and 
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immunohistochemistry to measure vessel formation, cardiomyocyte viability, and 
apoptosis were performed on isolated hearts immediately after MRI acquisition. 
1.3.2 Specific Aim 2 
Characterize the optimal bioreducible polymer carrier to deliver genetic material 
to cardiomyocytes and determine the protective effects of siRNA-mediated BNIP3 
knockdown on hypoxic cardiomyocytes. 
Selection of an ideal polymer gene delivery agent for use in vivo is a multifaceted 
process. We identified that a novel poly(amido amine) polymer synthesized by our lab, 
arginine-grafted poly(cystaminebisacrylamide diaminohexane) (referred to as arginine-
grafted bioreducible polymer; ABP), showed the ideal characteristics of high transfection 
efficiency, low cytotoxicity, and prolonged stability [24, 25]. Cardiomyocytes (especially 
those from a primary animal source) have long been known to be notoriously difficult to 
transfect [26, 27]; thus, the identification of the optimal polymer to obtain high 
transfection efficiencies with minimal toxicity is paramount. 
1.3.3 Specific Aim 3 
Determine if a reduction of BNIP3 levels in rat cardiomyocytes after acute 
myocardial ischemia/reperfusion injury results in increased cell survival, decreased 
apoptosis, and retention of heart function in an in vivo rat model. 
We used a rat coronary ligation model of myocardial infarction to evaluate the 
effectiveness of polymer-mediated BNIP3 mRNA knockdown in increasing 
cardiomyocyte survival and subsequently retaining heart function. Rats were randomly 
assigned to one of five groups: 1) sham operated control (thoracotomy only), 2) coronary 
ligation ischemia/reperfusion control, 3) siBNIP3 delivered intramyocardially via 
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arginine-grafted bioreducible polymer (siBNIP3:ABP), 4) siBNIP3 delivered 
intramyocardially alone (naked siRNA), and 5) siLuciferase delivered intramyocardially 
via arginine-grafted bioreducible polymer (siLuc:ABP). Two weeks after surgery, heart 
function and global and regional ventricle geometry were measured via magnetic 
resonance imaging (MRI). Additionally, histological and immunohistological analyses 
were performed on isolated hearts to determine infarct size, cardiomyocyte geometry, 
cardiomyocyte viability, BNIP3 expression, and degree of apoptosis via TUNEL assay.  
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MYOCARDIAL INFARCTION, GENE THERAPY, AND POLYMER 
 
GENE CARRIERS: BACKGROUND AND LITERATURE REVIEW 
 
 
2.1 Myocardial Infarction 
Cardiovascular disease is the most common cause of death in developed nations 
and accounts for one out of every three deaths in the United States for a total of 811,900 
deaths in 2008 [1]. Of the various forms of cardiovascular disease, coronary heart disease 
is the deadliest, accounting for half of all reported cardiovascular disease-related deaths 
and 405,300 deaths in 2008 [1]. Myocardial infarction (MI), or heart attack, is a 
particularly deadly form of heart disease (1 out of 20 deaths, 2008 total of 134,000 deaths 
[1]) and is characterized by a loss of blood flow to the heart, typically due to coronary 
artery blockage, resulting in ischemic tissue death. Even when a person survives acute 
MI, the long-term prognosis is daunting, with an average survival of around six years [1]. 
The poor prognosis after MI is due to both microscopic cellular and macroscopic 
geometric damage leading to deterioration in heart function and progression towards 
heart failure. The deteriorated heart performance is the result of further death of cardiac 
cells and MI-initiated remodeling of the left ventricle (LV), a process that has been 
shown to occur immediately after MI and which may continue for the duration of the 
patient’s life [2-4]. The remodeling ultimately results in LV dilation, which has been 
shown to be a primary determinant of morbidity and mortality [5]. Due to the high 
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incidence of MI and the limited treatment options in preventing progression to heart 
failure, many researchers are attempting to develop treatments that will limit LV 
remodeling and retain heart function. 
2.2 Left Ventricular Remodeling 
Left ventricular remodeling after myocardial infarction is a complex, progressive, 
and pathological transformation whereby the ventricle changes shape, size, and 
composition after MI, leading to decreased function [4, 6]. The heart’s capacity to 
remodel is a necessary adaptive process for normal growth, development, and 
compensation for exercise stress, but after MI, the process can become maladaptive, 
decreasing the performance of the heart. Remodeling of the LV has been shown to begin 
as soon as minutes after a myocardial infarction occurs and can continue for many 
months and even years [7]. These changes occur due to pathological alterations in the 
myocardium, including cardiomyocyte apoptosis, cardiomyocyte hypertrophy, fibroblast 
proliferation, and increased intercellular fibrosis. Slowing or eliminating remodeling is of 
the utmost clinical value as the degree of remodeling has been shown since the 1970s to 
correlate highly with poor prognosis, future risk for heart failure, and increased 
mortality [5, 8, 9]. 
The process of LV remodeling is regulated by a number of factors, including 
genetic, mechanical, and hormonal signals [10]. As a result of these multifaceted signals, 
remodeling occurs at three distinct levels within the heart: at the ventricular level, 
involving changes in volume, wall thickness, and shape; at the cellular level, involving 
changes in cell volume, length, number, and cross-sectional area; and at the molecular 
level, involving changes in gene expression due to neurohormonal signals. 
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2.2.1 Molecular and Cellular Remodeling 
Remodeling begins with activation of an array of paracrine, neuroendocrine, and 
autocrine factors. These factors are quickly upregulated in response to myocardial injury, 
mechanical wall stress, alteration in hemodynamics and blood pressure, hypoxia, and 
increased reactive oxygen species (ROS). Hypotension incident to myocardial infarction 
activates the renin-angiotensin-system (RAS) [11], increases secretion of natriuretic 
peptides [12], and increases norepinephrine and other catecholamine production by the 
adrenal medulla [13, 14]. MI also causes activation of inflammation pathways by 
triggering a cytokine cascade initiated by tumor necrosis factor alpha (TNF-α) [15]. 
Dysfunction in the myocardial wall activates angiotensin II type (AT) stretch receptors, 
inducing hypertrophy through angiotensin II (Ang II) [16]. Hypoxia upregulates a large 
number of genes with hypoxia inducible factor- (HIF) sensitive hypoxia response 
elements (HREs) and reperfusion causes a large degree of damage due to rapid increases 
in reactive oxygen species [17-19]. Collagenases and proteins that degrade the 
extracellular matrix like matrix metalloproteases (MMPs) are also upregulated, causing 
degradation of the normal connective tissue and remodeling of the extracellular 
matrix [20, 21]. 
2.2.2 Geometric Ventricular Remodeling 
Ultimately, the cellular and molecular changes that occur above present as global 
and regional changes in the LV. Due to the changes in cardiomyocyte numbers, size, and 
utility, the LV begins to alter in shape and function. The walls of the ventricle begin to 
thin due to increased fibrosis and cardiomyocyte slippage [22]. Loss of cardiomyocytes 
via necrosis produces an inflammatory response with fibroblast proliferation and collagen 
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deposition to replace the dead cells. The remaining cells are embedded and isolated 
within the fibrotic scar and the rhythmic contraction of the cardiomyocytes begins to 
suffer as a result [6, 23]. The thinning walls increase the mechanical strain within the 
heart, causing the ventricle to progressively deform and expand [24]. This expansion 
leads to increased chamber volume at both systole and diastole with increased LV 
diameters, especially through the infarct zone and towards the apex of the heart [25]. Due 
to the serious implications of LV remodeling following MI and its high correlation to 
heart failure rates, researchers and clinicians are focused on surgical and pharmacological 
strategies to limit the extent of remodeling that occurs. 
2.3 Surgical and Pharmacological Management of Myocardial Infarction 
In the event of acute myocardial infarction, the most pressing issue is to eliminate 
the occlusion, reestablishing blood flow to the myocardium. Rapid restoration of blood 
flow to the myocardium as measured by time to reperfusion has been consistently 
demonstrated as the most effect means of increasing patient survival while lessening 
infarct size [26, 27]. Achieving quick time to reperfusion is a difficult process, however, 
as there are many steps that must occur rapidly from when a patient first experiences 
symptoms of an acute MI to when the patient is treated for the condition. A patient 
suffering an acute MI must first be quickly transported to the hospital, admitted to the 
emergency department, triaged, and diagnosed, and then finally treated with either 
thrombolytics or angioplastic percutaneous coronary intervention (PCI) [28]. In 
complicated cases requiring multivessel replacement, surgical coronary artery bypass 
grafting (CABG) is performed. 
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2.3.1 Drugs for Early Reperfusion 
Thrombolytic therapy involves the use of fibrinolytic agents to lyse the 
thrombus/thrombi occluding the coronary arteries. There are three major classes of 
thrombolytic drugs in use today: the tissue plasminogen activators (tPAs) alteplase, 
reteplase, and tenecteplase; the streptokinases anistreplase, and natural streptokinase; and 
urokinase. All three of these drug classes work on the same target within the same clot 
formation pathway—plasminogen. Plasminogen is the inactive precursor to the active 
fibrinolytic plasmin and is activated via cleavage of a signal peptide to liberate active 
plasmin. 
The tPAs are all enzyme mimetics of endogenous tPA, which is a proteolytic 
enzyme released by endothelial cells in response to signals such as hemostasis. The 
enzyme tPA and its drug analogs function by binding to fibrin where it activates 
plasminogen that is also bound to the fibrin clot. This localized effect gives the tPA class 
of fibrinolytics a slight advantage over other fibrinolytic drug classes as it produces more 
local fibrinolysis with less systemic lytic effect [29]. Alteplase is a recombinant version 
of the endogenous tPA enzyme but suffers from an extremely short systemic half-life of 
approximately 5 minutes [30]. Reteplase and tenecteplase are both recombinant mutant 
forms of tPA with modifications to increase their circulating half-life to 13–16 minutes 
and 90–130 minutes, respectively [30]. 
Similar to the tPA class of drugs, streptokinase also acts on plasminogen, but does 
not possess enzymatic activity to convert plasminogen to plasmin. Instead, it induces a 
conformational change in plasminogen, which exposes the plasminogen active site, 
increasing the liberation of plasmin. Since the introduction of the newer tPA class, 
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streptokinase is not commonly used in a clinical setting as tPAs have been shown to be 
more effective [31]. Urokinase is not commonly utilized for acute MI as it is not 
indicated for the condition, being used instead to clear pulmonary emboli. 
The use of thrombolytics for acute MI is very time dependent. After 
approximately 2 hours, fibrin cross-linking within the clot is extensive and the clot is 
more compact, making lysis more difficult [26, 32]. Thrombolysis of aged clots requires 
higher fibrinolytic concentrations and is accompanied by increased risk of hemorrhage. 
2.3.2 Angioplastic Intervention for Reperfusion 
The other common method to restore myocardial blood flow and remove coronary 
occlusion is primary percutaneous coronary intervention (PCI). PCI involves inserting a 
guided catheter through a peripheral (usually femoral) artery to gain direct access to the 
coronary artery blockage. Meta-analyses have consistently shown better long-term 
outcomes for PCI versus thrombolytic therapy, reducing short-term mortality, 
reinfarction, stroke, and long-term death [33]. 
PCI was first used for revascularization in the 1970s by inserting a catheter with a 
balloon tip through the vasculature and through the coronary blockage then expanding the 
balloon to expand the artery, restoring blood flow [34]. While percutaneous balloon 
angioplasty revolutionized the way coronary artery diseases were treated, the 
effectiveness of the procedure was limited due to side effects such as thrombus formation 
and rapid coronary artery reocclusion. To improve upon balloon angioplasty, other 
devices were developed that removed the plaque blockage or physically left a device such 
as a stent to hold the vessel open. Bare metal stents were introduced in 1986 [35] and 
were further improved in 2003 by coating bare metal stents with a drug-eluting polymer 
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to form drug-eluting stents [36, 37]. The drug-eluting stents release pharmacological 
agents to limit neointimal hyperplasia, a process where the damage to the endothelial wall 
causes continued growth and division of endothelial and smooth muscle cells into the 
intimal space of the vessel, eventually restricting blood flow and occluding the vessel 
[38, 39]. Current drug-eluting stents contain antiproliferative agents such as sirolimus and 
paclitaxel. Early trials showed excellent prevention of restenosis, with 0% restenosis 
using a sirolimus-eluting stent versus 26.6% restenosis with a bare metal stent at 
6 months [40]. Similarly, some of the early trials with paclitaxel-eluting stents showed 
the same 0% 6-month restenosis rate versus a 10% restenosis rate with standard 
stents [41]. 
While the short-term success of drug-eluting stents is extremely high, long-term 
use of the devices is accompanied by risks that are not seen in patients who receive bare 
metal stents. Some of these complications include late and very-late thrombosis [42, 43], 
hypersensitivity immune response [44, 45], delayed healing [46], and endothelial 
dysfunction [47]. Recently conducted meta-analyses of trials using drug-eluting stents 
confirms that their use is not without unique risks, but shows that the benefits are still in 
favor of using the newer stents over bare metal stents [48, 49]. 
Next generation drug-eluting stents are already in development and are currently 
being tested in humans. Improvements include new biodegradable polymers with 
enhanced biocompatibility that do not induce as serious an inflammatory response as the 
current nonbiodegradable polymers [50], updated antiproliferative drugs, and polymer-
free drug-eluting stents [51, 52]. 
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2.3.3 Pharmacological Management Post-MI 
Patients managing the after-effects of myocardial infarction can be placed on a 
variety of pharmacological agents designed to lessen the risk factors for heart failure. 
These drugs positively affect the heart by either increasing the contractile force of 
remaining cardiomyocytes or by reducing the workload on the heart. These drugs include 
angiotensin-converting enzyme (ACE) inhibitors, ß-blockers, diuretics, angiotensin 
receptor blockers, aldosterone antagonists, hydralazine and isosorbide dinitrate, and 
digitalis glycosides. 
The use of inotropic agents in heart failure is usually managed with care as most 
inotropic agents (with the exception of digitalis glycosides) have shown increased 
mortality rates in heart failure patients [53, 54]. However, while the use of inotropes may 
shorten the patient’s lifespan, the quality of life of patients on these drugs is dramatically 
improved. Inotropic agents such as digoxin, phosphodiesterase inhibitors (milrinone), and 
ß-receptor agonists (dopamine and dobutamine) exert their positive hemodynamic effects 
by increasing cardiac output while reducing, to a lesser degree, neurohormonal activation. 
Angiotensin receptor blockers and ACE inhibitors are some of the most common 
drugs used post-MI and have demonstrated their ability to both slow, stabilize, and even 
mildly reverse pathological remodeling [55]. Due to neurohormonal activation after MI, 
the sympathetic nervous system and RAS are activated, leading to high levels of 
angiotensin, aldosterone, and norepinephrine in the myocardium. Increased myocardial 
levels of norepinephrine are especially problematic as norepinephrine is proapoptotic to 
the myocardium [56, 57]. Large multicenter trials have demonstrated increased survival, 
retention of function, fewer hospitalizations, and retained heart geometry in MI patients 
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receiving ACE inhibitors [58-61]. Efficient inhibition of the RAS using angiotensin-
receptor blockers has also been shown to provide a survival benefit and limit 
remodeling [62, 63]. 
ß-blockers are used to counteract the effects of sympathetic nervous system 
activation and are well known to reduce remodeling and limit progression to heart failure. 
The beneficial mechanism of these drugs comes from negative chronotropic effects on 
heart rate, resulting in reduced intramyocardial neurohormone levels, decreased oxygen 
demand, and decreased infarct expansion [64]. Clinical studies have repeatedly 
demonstrated this benefit with long-term and short-term improvement seen in infarct 
expansion, LV ejection fraction, and myocardial dysfunction [65-67]. 
Aldosterone antagonism is hypothesized to produce beneficial effects in post-MI 
patients through inhibition of myocardial fibrosis [68, 69]. Studies evaluating aldosterone 
antagonists in combination with angiotensin receptor blockers showed improvement in 
LV mass, end diastolic/systolic volumes, and ejection fraction [70]. 
Patients who have undergone some form of PCI receive prophylactic treatment to 
prevent recurrence of atherosclerosis and thrombosis. Most guidelines recommend dual 
antiplatelet therapy with life-time, low-dose aspirin, and thienopyridine prescribed for 
one year. Statin drugs are also prescribed to help reduce serum cholesterol levels, ß-
blockers are used to decrease cardiac workload and arrhythmias, and lifestyle 
management changes are recommended to lower the risk for recurrence. 
The current first-line therapies of angiotensin and ß receptor blockade, and ACE 
inhibition, have clearly been demonstrated to aid in patient outcome and limit 
remodeling; however, pathological remodeling still continues in most patients. Because 
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of this, novel targets and treatment strategies such as antiapoptosis, antiinflammation, 
matrixmetalloprotease inhibition, cell-based, and proangiogenic therapies are currently 
being evaluated to prevent remodeling and increase LV function and patient survival. 
2.3.4 Decreasing Infarct Size at Primary Intervention 
Several strategies to reduce infarct size by limiting the extent of injury caused by 
reperfusion are actively being investigated. Some success has been observed in trials 
using adjuvant adenosine to limit infarct size by reducing free radical formation and 
neutrophil accumulation. The AMISTAD I trial found that administration of adenosine 
reduced anterior infarct size by 33% but had no effect on inferior infarctions [71]. Further 
investigation in the AMISTAD II trial found a nonsignificant trend towards smaller 
infarct sizes with low-dose adenosine but significantly smaller infarct sizes with high 
doses [72]. 
Some progress has been made in using therapeutic hypothermia to reduce the 
degree of reperfusion injury. Therapeutic hypothermia requires lowering the temperature 
of the heart either locally or by cooling the whole body to approximately 33 °C. This 
approach has demonstrated cardioprotective capabilities in animal models [73, 74] and in 
human studies [75]. However, it suffers from several limitations, including uncontrollable 
shivering, decreased drug metabolism, and the prolonged period required to achieve 
adequate cooling (approximately 1 hour) [76]. 
2.4 Gene Therapy for Recovery of Myocardial Function 
Significant gains have been made in recent years in pharmacological therapies of 
the infarcted myocardium. While these gains have improved post-MI life expectancy and 
helped limit progression to heart failure, the therapeutic regimens are mainly focused on 
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decreasing the burden on the injured heart. In order to more fully treat the infarcted heart, 
therapies are actively being sought that can regenerate functional myocardium or prevent 
the loss of cardiomyocytes caused at the time of injury and afterwards. Gene therapy is 
one technique that is being investigated as a method for protecting the myocardium and 
preventing the loss of cardiomyocytes. 
To date, there have been over 1,800 gene therapy clinical trials performed in 
humans [77]. Successful gene transfer in the cardiovascular system was first seen as long 
ago as 1989 [78]. Since that time, the popularity of cardiovascular diseases as a target for 
gene therapy has continued with cardiovascular diseases second only to cancer in 
popularity for gene therapy indications. Of all the almost 2,000 gene therapy clinical 
trials performed to this point, 155 or 8.4% of all trials have been indicated for the 
treatment of cardiovascular diseases [77]. 
While many gene targets have been investigated as potential strategies to treat 
cardiovascular disease in animal models, thus far, the overwhelming majority of human 
trials have utilized angiogenic factors to treat the disease [79]. The only other target 
evaluated in humans is sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
(SERCA2a). This target was recently evaluated in the Calcium Up-Regulation by 
Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial and 
showed functional improvement after treatment with an adeno-associated virus 1 AAV1-
SERCA2a vector [80, 81]. 
In addition to the angiogenic targets used in human clinical trials, a wider array of 
targets have been evaluated in animal models and shown to prevent left ventricular 
remodeling. Other gene therapy approaches include targeting extra-cellular matrix 
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degradation, via TGF-ßR [82], decorin [83], and integrin-linked kinase expression [84]. 
Other strategies utilize gene transfer to minimize cell death and include targeting 
antiapoptosis or prosurvival factors after ischemia/reperfusion injury. These targets 
include soluble Fas [85], heme oxygenase-1 [86], targets such as midkine growth factor 
[87], Bcl-2 [88], and the TNF-α receptor-1 [89]. Additionally, previous work in our 
laboratory has investigated VEGF expression in a plasmid under control of a hypoxia-
specific RTP-801 promoter [90-92], using a novel cholesterol-conjugated cationic 
polymer and a terplex system composed of DNA, low density lipoprotein, and stearyl-
poly-L-lysine [92]. 
In addition to plasmid-based approaches, several groups have utilized gene 
therapy to deliver siRNA to the myocardium to lower mRNA levels of deleterious 
proteins. Some of the siRNA targets investigated include PHD2 [93-95], SHP-1 [96], 
ALOX5 [97], and PTP-1B [98]. While these groups have mainly focused on the delivery 
of prosurvival, protective, and general antiapoptotic genes, no one has been able to 
demonstrate the utility of a system to protect from more specific hypoxia-induced 
apoptosis. 
2.5 Tissue Oxygen Levels and Hypoxia Response 
Cellular response to oxygen is a complex and tightly regulated process, mediated 
by a myriad of proteins (Figure 2.1). One important protein for regulating tissue O2 
response is the transcription factor hypoxia inducible factor-1 (HIF-1). HIF-1 is a 
heterodimeric protein consisting of a HIF-1α and HIF-1ß subunit (HIF-1ß is also known 
as the aryl hydrocarbon receptor nuclear translocator, ARNT). While HIF-1ß is 








Figure 2.1. The cellular oxygen response mediated through HIF-1α. 
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[99-101], HIF-1α levels are kept low under normoxic conditions via posttranslational, 
oxygen-dependent degradation [102]. During normoxia, the 402/564 prolyl residues of 
HIF-1α are hydroxylated by the oxygen-dependent prolyl hydroxylases (PHD1, PHD2, 
and PHD3) [103]. The enzymatic activity of these hydroxylases is dependent on both iron 
and molecular O2 availability. After HIF-1α has been hydroxylated, it binds to the von 
Hippel-Lindau tumor suppressor protein (pVHL) [104]. Ubiquitination of HIF-1α is 
mediated by the pVHL complex, targeting HIF-1α for proteasomal degradation. Under 
hypoxic conditions, the PHDs lack the molecular O2 necessary for their enzymatic action, 
resulting in decreased HIF-1α degradation. HIF-1α then translocates to the nucleus where 
it is free to heterodimerize with HIF-1ß to form the active transcription factor HIF-1. This 
transcription factor induces the upregulation of genes containing hypoxia response 
elements (HREs) in their promoters, allowing for genetic adaptation to decreased oxygen 
levels [105]. While the primary physiological response to lowered O2 levels is an 
adaptive and prosurvival response, if normal levels of O2 are not restored, the cell will 
ultimately undergo apoptosis, autophagy, or necrosis. 
2.6 The Proapoptotic Protein BNIP3 
The myocardium has historically been found to be highly resistant to apoptosis 
with an average observed apoptotic rate of 1 in 100,000 cardiomyocytes [106]. This low 
level of observed apoptosis is thought to be at least partially due to high myocardial 
expression levels of caspase inhibitors such as the apoptosis repressor with caspase 
recruitment domain (ARC) and X-linked inhibitor of apoptosis protein (XIAP) [107]. In 
diseased hearts, however, the rate of apoptosis has been shown to dramatically increase 
over 200-fold for both ischemic cardiomyopathies and idiopathic dilated 
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cardiomyopathies [106]. While cardiomyocytes are capable of spontaneous regeneration 
after myocardial infarction, the degree to which they regenerate is insufficient to 
compensate for the increased rate of cell loss [108, 109]. With the balance of cell death 
and regeneration tipped towards cell death, the heart gradually loses more and more 
cardiomyocytes and progresses in a path towards heart failure. 
Apoptosis and cell death following acute myocardial infarction has been shown to 
be readily detectable in humans especially within a one-week time frame after MI. 
Studies have shown that apoptosis peaks within the first few days, decreasing rapidly 
after four days to a much lower level [110]. 
An important cellular mediator of hypoxia-inducible cell death is Bcl-
2/adenovirus E1B nineteen-kilodalton interacting protein 3 (BNIP3). BNIP3 is an HRE-
containing proapoptotic protein belonging to the Bcl-2 family and is one of the most 
highly upregulated proteins in response to hypoxia [111-113]. Human BNIP3 is a 194-
amino acid protein with several domains that dictate its structure. BNIP3 has a 
transmembrane domain at residues 164–184, which allows it to insert into the 
mitochondrial membrane and homodimerize with other BNIP3 proteins in the membrane 
to form an ion channel [114, 115]. BNIP3 also has a Bcl-2 homology domain 3 (BH3) at 
residues 104–119, which allows it to bind with the antiapoptotic Bcl-2 [116]. Finally, 
BNIP3 also has an evolutionarily conserved cysteine residue at amino acid 64, which is 
thought to increase BNIP3 stability under conditions of oxidative stress [117]. Under 
oxidative conditions such as after MI when high levels of ROS are present in the 
myocardium, the cytosolic compartment switches from a reductive environment to an 
oxidative environment. When this occurs, disulfide bonds become more favorable and 
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stable. The BNIP3 cysteine, which is located on the cytosolic side of the protein when it 
inserts into the mitochondrial membrane, forms a stabilizing disulfide bonds with its 
homodimer, increasing its activity and depolarizing the mitochondrial membrane [117]. 
While BNIP3 has been studied extensively, the exact mechanisms by which it 
brings about cell death are not yet completely understood. However, it has been shown 
that cells where BNIP3 is upregulated can undergo one of at least three pathways that can 
lead to death: apoptosis, autophagy, or necrosis (Figure 2.2). As BNIP3 plays such a 
pivotal role in the regulation of the hypoxia death response, it is a prime candidate for 
gene therapy to selectively disable hypoxia-inducible cell death [118]. 
2.6.1 BNIP3-Regulated Apoptosis 
It is postulated that BNIP3 induces cell death through localization to the 
mitochondrial membrane and depolarizing the membrane [114]. In some cell types, the 
localization of BNIP3 to the mitochondria causes cytochrome c release, initiating the 
caspase cascade and committing the cell to apoptosis [119]. However, in other cells such 
as neurons, BNIP3 induces endonuclease G release from the mitochondria but does not 
cause cytochrome c release, causing caspase-independent cell death [120]. 
2.6.2 BNIP3-Regulated Autophagy 
Autophagy is a catabolic cellular process by which proteins and subcellular 
organelles are compartmentalized, and broken down by lysosomal degradation. In the 
heart and other tissues, autophagy is a normal process allowing cells to eliminate 
damaged proteins and organelles while scavenging many of the nutrients contained in the 





Figure 2.2. BNIP3-regulated death pathways. Adapted from [115] 
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not necessarily end in cell death. Autophagy is a normal cellular process that is observed 
in some healthy cell types [121-123]. The process allows for recycling of dysfunctional 
organelles, and defective cytoplasmic proteins without committing the cell to a death fate. 
In some animal models of repetitive ischemia/reperfusion, cardiac injury autophagy has 
been observed as a precursor to eventual apoptosis, with autophagic cell death occurring 
at a later time than apoptotic cells [124]. This observation would suggest a protective 
mechanism, giving cardiomyocytes extra time to acclimate to the disturbed oxygen and 
nutrient status post-ischemia/reperfusion and to attempt to avoid apoptosis by removing 
damaged intracellular structures. 
The autophagic role of BNIP3 and its related family member Nix/BNIP3L in 
cardiomyocytes has received a great deal of attention over the past years. The role of 
BNIP3 in inducing autophagy is thought to be due to its interaction with the antiapoptotic 
Bcl-2. This antiapoptotic protein plays a role in sequestering beclin-1, a protein which is 
known to induce autophagy. Since BNIP3 has a BH3 domain through which it can bind 
Bcl-2, BNIP3 can act as a competitive inhibitor of Bcl-2 for beclin. In periods of high 
BNIP3 expression such as hypoxia, BNIP3 displaces beclin by binding to Bcl-2, causing 
beclin to initiate autophagy [125, 126]. 
2.6.3 BNIP3-Regulated Necrosis 
Unlike the death pathways listed above which are energy- and ATP-dependent, 
necrosis is a passive process. Necrosis usually occurs as a result of overwhelming injury, 
which causes cellular swelling, dysregulation of organelle function, and ultimately leads 
to rupture of the cell membrane. This rupture rapidly releases cellular contents to the 
extracellular environment, damaging neighboring cells and causing inflammation. 
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BNIP3 has been shown to play a role in the necrosis of neurons [127, 128], tumor 
cells [129-131], and cardiomyocytes [117, 132]. BNIP3-mediated necrosis is thought to 
occur through interactions at the mitochondrial membrane similar to its site of action for 
inducing autophagy and apoptosis. However, over-activation of BNIP3 at the 
mitochondrial membrane is thought to rapidly push the cell to a necrotic as opposed to 
autophagic fate. In addition to the conserved transmembrane and BH3 domain, BNIP3 
also has a conserved cysteine residue at position 64 located on the cytosolic side where 
BNIP3 inserts into the mitochondrial membrane [117]. When the cytoplasmic 
compartment shifts from a predominantly reductive environment to a predominantly 
oxidative environment under oxidative stress situations such as is experienced during 
reperfusion injury in cardiomyocytes, this cysteine residue forms a disulfide bond with 
the cysteine residue on another BNIP3 protein forming a covalent homodimer [116, 117]. 
This increase in activity on the mitochondrial membrane is thought to push the cell 
towards a necrotic as opposed to autophagic cell death [133]. 
2.7 RNA Interference and siRNA 
RNA interference (RNAi) refers to the endogenous cellular pathway by which 
double-stranded RNA (dsRNA) is processed into small interfering RNA (siRNA) that can 
target mRNA transcripts for gene silencing. 
The RNAi phenomenon was originally observed by Guo and colleagues in 1995. 
While performing gene function studies in C. elegans, they detected a sense strand 
sequence as the complementary antisense sequence for repressing gene expression [134]. 
This observation was further investigated by Fire et al. in 1998 and they published a 
seminal paper demonstrating that introduction of double-stranded RNA sequences 
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produced a more potent and specific interference effect than either the sense or antisense 
strand alone [135]. This discovery initiated a period of rapid research further elucidating 
the mechanism and potential impact of RNAi. A summary of many important 
publications highlighting the discovery and development of RNAi can be seen in 
Table 2.1. 
Using siRNA to target a specific protein is particularly attractive because of the 
ability of siRNA to knockdown one target while essentially sparing all other proteins. 
Careful design of siRNA constructs is performed by using algorithms that optimize 
siRNA efficiency, analyzing selected constructs for lack of shared homology to other 
proteins by utilizing NCBI Blast searches, and by screening several siRNA constructs to 
determine the sequence with the highest knockdown efficiency and fewest off-target 
effects. Additionally, published sequences that have been shown to effect efficient 
knockdown of the target can be used [136-138]. 
Many researchers use siRNA as a laboratory tool for the analysis of gene function 
and to easily and rapidly decrease specific protein levels. However, many people have 
also been looking at siRNA as a potential therapeutic. While siRNA possess many 
attributes that make them ideal candidates for therapeutics, there are inherent issues with 
employing siRNA in vivo. Nucleotides have extremely short extracellular half-lives 
(seconds to minutes in the circulation [139]). Also, their large size (average 13.5 kDa), 
charged phosphodiester backbone, and hydrophilicity impede their ability to cross cell 
membranes. Therefore, a delivery vehicle is needed to protect the nucleotides from 





Table 2.1. Seminal Publications in the History of RNAi Discovery 
 
 
Year Author Organism Discovery Reference 
1995 Guo et al. C. elegans RNA sense strand interferes with gene expression [134] 
1998 Fire et al. C. elegans Double-stranded RNA reduces gene expression more 
potently than sense or antisense strands alone 
[135] 
2000 Zamore et al. D. melanogaster Dicer protein processes double-stranded RNA to 21–23 
nt fragments 
[140] 
2001 Elbashir et al. Mammals First observation of RNAi in mammalian cells [141] 
2002 Paddison et al. Mammals RNAi through expressed short hairpin RNA (shRNA) [142] 
2004 Acuity Pharmaceuticals H. sapiens First human Phase I clinical trial using siRNA  
2010 Davis et al. H. sapiens Targeted systemic polymer nanoparticle siRNA delivery 




2.7.1 siRNA Therapy and Clinical Trials 
Over forty clinical trials utilizing siRNA or shRNA have been performed or are in 
progress (Table 2.2). While many of these trials are still early-stage (Phase I and II), at 
least one trial is in late-stage Phase III trials. Despite the large number of clinical trials, 
no candidates have yet gained FDA approval.  
The first clinical trials investigating RNAi were performed with naked, 
unmodified siRNA and were delivered either by local injection to the therapeutic site or 
via inhalation to the lungs. Even when the first trials began, the limitations of poor 
siRNA bioavailability were understood. Therefore, ocular diseases with a separated 
physiological compartment that allowed easy access and protection from rapid 
degradation in the circulation were used. However, the knockdown even in these isolated 
compartments has not been very high and while some benefit was observed in early trials 
targeting age-related macular degeneration (AMD), it has been hypothesized that the 
observed benefit may be from activation of toll-like receptors (TLRs) and not target 
knockdown [146, 147]. 
While the clinical success of siRNA over the past decade has been disappointing, 
there is still hope for its therapeutic potential. A better understanding of the limitations of 
siRNA therapy, including off-target effects, short effect duration, low efficacy, and TLR 
activation has led to marked overall improvements over the years. New siRNA 
technologies, including improved siRNA chemical modifications to increase availability 
and decrease degradability, and development of efficient viral and nonviral delivery 
systems to increase siRNA delivery to target cells, are currently being investigated in 





Table 2.2. Current siRNA and shRNA Clinical Trials 
 
 





 Cancers          
 Bcr-Abl siRNA Bcr-Abl Anionic liposome CML U of Duisburg I Completed N/A 2010  
 FANG vaccine furin/ TGFß1 
TGFß2 
Autologous ex vivo 
electroporated GMCSF cells 
Solid cancers Gradalis, Inc. I Recruiting NCT01061840 Dec ’09  
    Advanced cancer Gradalis, Inc. I Recruiting NCT01505153 Feb ’12  
    Melanoma Gradalis, Inc. II Recruiting NCT01453361 Oct ’11  
    Ovarian cancer Gradalis, Inc. II Recruiting NCT01551745 Mar ’12  
    Ovarian cancer Gradalis, Inc. II Recruiting NCT01309230 Feb ’11  





Ex vivo transfected dendritic 
cells 
Melanoma Duke University I Recruiting NCT00672542 Jan ’08  
 TKM-080301 PLK1 Liposome (cationic and 
fusogenic lipids with PEG) 
Cancer Tekmira I Recruiting NCT01262235 Dec ’10  
    Primary/secondary 
liver cancer 
NCI I Completed NCT01437007 Aug ’11  
 ALN-VSP02 KSP VEGF Liposome (mixture of 
cationic and fusogenic lipids 
with PEG) 
Liver cancer Alnylam I Completed NCT00882180 Mar ’09  
    Solid tumors Alnylam I Ongoing NCT01158079 Jul ’10  
 Atu027 PKN3 lipoplex Solid tumors Silence 
Therapeutics 
I Recruiting NCT00938574 Jun ’09  
 CALAA-01 RRM2 cyclodextrin and PEG 
nanoparticle with transferrin-
targeting 
Solid tumors Calando I Ongoing NCT00689065 May ’08  
 siG12D LODER KRASG12D LODER biodegradable 
polymer matrix 
Pancreatic cancer Silenseed 0/I Recruiting NCT01188785 Jan ’11  
    Pancreatic cancer Silenseed II Not yet open NCT01676259 Sep ’12  
 CEQ508 ß-catenin shRNA in E. coli Colon cancer Marina I On-hold N/A 2010  
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 Ocular disorders          
 Bevasiranib VEGF Naked siRNA Wet AMD Opko Health I Completed NCT00722384 Aug ’04  
      II Completed NCT00259753 Jul ’05  
      III Terminated NCT00499590 Aug ’07  
      III Withdrawn NCT00557791 Nov ’09  
    Diabetic macular 
edema 
Opko Health II Completed NCT00306904 Jan ’06  
 AGN211745 (Sirna-027) VEGF-R1 Naked siRNA AMD Allergan/Sirna I/II Competed NCT00363714 Nov ’04  
    AMD Allergan II Terminated NCT00395057 Jan ’07  
 PF-04523655 RTP-801 Naked siRNA Wet AMD Quark/Pfizer I Completed NCT00725686 Feb ’07  
    Diabetic retinopathy Quark/Pfizer II Terminated NCT00701181 Jun ’08  
    Wet AMD Quark/Pfizer II Completed NCT00713518 Nov ’09  




Quark II Recruiting NCT01445899 Feb ’12  




Quark I Ongoing NCT01064505 Feb ’10  
 SYL040012 Adrenergic receptor 
ß2 
Naked siRNA Glaucoma, ocular 
hypertension 
Sylentis I Completed NCT00990743 Sep ’09  
      I/II Recruiting NCT01227291 Oct ’10  
 SYL1001 TrpV1 Naked siRNA Dry eye, ocular pain Sylentis I Completed NCT01438281 Jul ’11  
 Inhaled formulations          
 ExcellairTM Syk kinase Unknown Asthma ZaBeCor II Unknown N/A 2009  
 ALN-RSV01 RSV nucleocapsid Naked siRNA RSV infection Alnylam II Completed NCT00496821 Jul ’07  
      II Completed NCT00658086 Apr ’08  
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 Miscellaneous disorders          
 PRO-040201 ApoB Liposome (mixture of 




Tekmira I Terminated NCT00927459 Jun ’09  
 ALN-TTR01 TTR Liposome (mixture of 





Alnylam I Completed NCT01148953 Jun ’10  
 I5NP P53 Naked siRNA AKI after 
cardiovascular 
surgery 
Quark I Completed NCT00554359 Aug ’07  
    AKI after 
cardiovascular 
surgery 
Quark I Terminated NCT00683553 May ’08  
    Delayed graft 
function in kidney 
transplantation 
Quark I/II Recruiting NCT00802347 Dec ’08  
 TD101 Keratin 6aN171K 
mutant mRNA 
Naked siRNA Pachyonychia 
congenital 
Transderm Ib Completed NCT00716014 Jan ’08  
 pHIV7-shI-TAR-CCR5RZ 
treated CD4 cells 
HIV Tat/rev, TAR, 
CCR5 
Ex vivo lentiviral-transfected 
autologous T-cells 
HIV City of Hope 0 Teminated NCT01153646 Apr ’10  
 
 
CML = chronic myelogenous leukemia; GMCSF = granulocyte macrophage colony stimulating factor; LMP = low molecular mass 
protein; MECL1 = multicatalytic endopeptidase complex subunit 1; PLK1 = polo-like kinase 1; NCI = National Cancer Institute; KSP 
= kinesin spindle protein; VEGF = vascular endothelial growth factor; PEG = polyethylene glycol; PKN3 = protein kinase N3; RRM2 
= ribonucleotide reductase subunit M2; VEGF-R1 = VEGF receptor 1; TrpV1 = capsaicin receptor; Syk = spleen tyrosine kinase; RSV 
= respiratory syncytial virus; ApoB = apolipoprotein B; TTR = transthyretin; p53 = tumor protein 53; AKI = acute kidney injury; HIV 
= human immunodeficiency virus; TAR = HIV trans-activation response element;CCR5 = CC chemokine receptor type 5. All data 
from www.clinicaltrials.gov, press releases, corporate websites, Vaishnaw et al. [144], and Burnett et al. [145]. 
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2.8 Gene Delivery and Carriers 
Naked DNA and RNA alone are highly inefficient drugs. In order for them to be 
successfully utilized in research or clinical settings, a carrier must be used or chemical 
modifications made to overcome the many barriers that prevent uptake of genetic 
material. In order to successfully introduce genetic material in the form of DNA or RNA 
to a cell, there are several barriers that must be surmounted. These barriers include: 1) 
rapid degradation in the circulation or extracellular space; 2) nonselective delivery to 
nontarget cells; 3) crossing the cell membrane; 4) escape from degradative compartments 
(i.e., the endosome and lysosome); 5) dissociation of cargo from the carrier; and 6) in the 
case of DNA, successful nuclear localization of the gene [149, 150]. 
Several methods for gene delivery which overcome these obstacles are currently 
available, but most techniques can generally be classified within two classes—viral and 
nonviral [151-154]. As their name implies, viral methods utilize viruses that have been 
attenuated to be nonreplicating and nonpathogenic and have been loaded with a gene for 
delivery. While viral gene vectors have evolved over millions, if not billions, of years to 
efficiently overcome the above-listed hurdles to transduce cellular organisms, they create 
safety concerns due to their immunogenicity and the potential for insertional 
mutagenesis. 
In order to circumvent these problems and generate delivery systems that can 
efficiently and selectively deliver genetic material to target tissues, a great deal of 
research has been done on developing nonviral methods for gene therapy. Nonviral 
methods consist of physical methods of transfection and the use of synthetic chemicals—
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most commonly cationic lipids and polymers. A comparison of the most common viral 
and nonviral delivery vectors can be seen in Table 2.3. 
2.8.1 Viral Gene Delivery 
Viral methods are extremely efficient, but their clinical usefulness is hampered by 
several major restrictions. Viral delivery is limited by problems with potential insertional 
mutagenesis [157, 158], difficulty and high expense incurred in large-scale 
manufacturing and quality control [159, 160], limited DNA cargo capacity, and 
immunogenicity. In 1999, an 18-year-old patient enrolled in an adenoviral gene therapy 
clinical trial for ornithine transcarbamylase deficiency experienced a fatal systemic 
inflammatory response against the adenoviral vector [161]. Later in 2000, a French group 
reported successful treatment of a group of children suffering from X-linked severe 
combined immunodeficiency (SCID-X1). However, in 2002, it was reported that two of 
the ten children in the trial had developed a form of leukemia [162]. Further analysis of 
the children led to the discovery that the retrovirus vector had integrated near a proto-
oncogene promoter, causing the development of leukemia [163]. 
2.8.1.1 Adenoviral Gene Therapy 
Adenoviruses were one of the first viral vector types used for gene therapy 
applications. Adenoviruses are a nonenveloped, double-stranded DNA-type virus with an 
approximately 36 kb genome encoding over 50 polypeptides. The adenovirus has a 
capacity of approximately 8.5 kb for foreign DNA, which is sufficient to accommodate 
most therapeutic genes. Some of the benefits of adenovirus vectors include their high 
efficiency, stability, nonintegrative nature, ability to infect both dividing and quiescent 





Table 2.3. Relative Comparison of Gene Transfer Methods 
 
 
 Vector Gene Transfer 
Efficiency 











Adenovirus ++++ ++++ +++ ++ +  
Lentivirus +++ +++ +++ ++ + HIV origins 
Retrovirus ++++ ++ ++++ ++ + Insertional mutagenesis 







 Naked + ++ + ++++ ++++  
Liposome ++ ++ ++ ++++ +++  
Polymer ++ + ++ ++++ ++++  
 
 
References [155, 156]. 
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However, most humans have been exposed to several adenoviral serotypes and 
have formed antibodies against the virus. As a result, when adenovirus vectors are 
administered to humans, almost 90% of the virus is eliminated within 24 hours. In 
addition to the rapid immune system clearance of adenoviral vectors, the capsid coat on 
the vectors has been known to stimulate acute and dangerous immune responses [161, 
166, 167]. The last disadvantage of using adenoviral vectors is the short duration of gene 
expression achieved in transfected cells. Typical expression times for adenoviral-
transfected cells are between 1–8 weeks [168, 169]. 
2.8.1.2 Retroviral Gene Therapy 
Retroviruses are small RNA viruses (7–11 kb genome) that replicate via a DNA 
intermediate and were also some of the first viral constructs applied towards gene therapy 
[170]. While the total genome is much smaller than the adenovirus genome, due to the 
simplistic nature of the virus, a roughly 8 kb therapeutic gene can be delivered without 
compromising the function of the virus [171]. The major benefit of retrovirus use is its 
ability to effect long-term, stable expression of therapeutic genes due to host 
chromosome integration. 
Limitations of the use of retroviral vectors include: relatively low transfection 
efficiency compared to other viruses, low viral stability, the inability to transduce 
nondividing cell types, and of course the risk of insertional mutagenesis [172]. 
2.8.1.3 Adeno-associated Viral Gene Therapy 
The adeno-associated viruses (AAV) are human parvoviruses that normally 
require the help of another virus such as adenovirus to infect cells. They possess a small 
4.7 kb genome of single-stranded DNA, which is converted to double-stranded DNA 
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after infection. The AAV can chromosomally integrate but shows less potential for 
insertional mutagenesis due to its preferential insertion to a specific site on the human 
chromosome 19 [173, 174]. The AAV family is one of the most actively investigated 
viral vectors currently due to the multiple advantages of the system. AAV vectors 
produce long-term expression, can efficiently transduce a wide variety of host cells with 
tissue-specific targeting capabilities, are a nonpathogenic virus, and they evoke a minimal 
immune response [175-177]. 
Several of the major limitations of AAV vectors include their small transgene 
packaging capacity, the still present risk of insertional mutagenesis, and difficulty in 
producing high viral titers sufficient for clinical trials and large-scale 
manufacturing [178, 179]. 
2.8.1.4 Other Viruses 
Other viruses that are commonly used for gene therapy include the lentiviruses, 
and the herpes simplex viruses. Lentivirus vectors are useful for their ability to transfect 
nondividing cell populations and maintain stable gene expression for extended periods 
[180]. Vectors based on herpes simplex contain a large genome of 152 kb of double-
stranded RNA, allowing for the insertion of large single transgenes or even multiple 
therapeutic sequences. 
Less common viral vectors include plus-strand RNA viruses such as Sindbis 
virus, hepatitis A, and polio. These viruses are more commonly investigated for viral 
immunization strategies since they produce high, yet transient, gene expression to evoke 
an immune response against the transduced cells. 
41 
 
2.8.2 Nonviral Delivery Systems 
 The nonviral delivery systems consist of methods such as injection of naked 
DNA [181]; delivery by gene gun [182]; by electroporation [183]; by ultrasound [184]; 
and by transfer to the highly perfused organs by hydrodynamic delivery [185, 186]. 
While these methods are capable of inserting genetic material into cells, they are neither 
practical nor efficient delivery systems. To overcome the limitations of the physical 
approaches above, chemicals such as lipids and polymers are used as quasi-viral 
mimetics. These chemicals allow for DNA protection from nuclease activity, relatively 
efficient uptake by cells, and tissue specificity when conjugated with a targeting motif. 
2.8.2.1 Naked Polynucleotide Delivery 
Some of the first methods used to transfer genetic materials to living tissue 
utilized unmodified DNA. Delivery of naked nucleotides without the assistance of any 
physical system is extremely inefficient due to the hydrophilic nature of DNA, its high 
molecular weight, and its negatively charged phosphate backbone. Thus, the dense 
negative charges are repulsed by the negatively charged cell membrane. However, 
delivery of naked nucleic acids has seen some clinical application in closed organ 
systems such as the eye, treating age-related macular degeneration (AMD) [187, 188]. 
2.8.2.2 Electroporation Gene Delivery 
Electroporation uses an electric field to temporarily increase permeability through 
the cell membrane. The electric pulses generated by this technique generate transient 
pores that allow polynucleotides to pass through. This technique has been used to effect 
gene transfer both in vitro and in vivo since 1982, and 1991, respectively [189, 190]. To 
perform in vivo electroporation, the DNA is injected first to the target area then an 
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electric field with varied pulse duration, and voltage is applied from two electrodes. This 
technique can achieve transfection efficiencies similar to those seen from viruses [191], 
but is best suited to models where localized gene transfer is desirable, the target is 
accessible by electrodes, and where electric pulses will not disrupt normal organ function 
(e.g., the heart). 
2.8.2.3 Ultrasound Gene Delivery 
Ultrasound-mediated delivery of polynucleotides functions in a similar manner to 
electroporation, but uses sound waves instead of electrical pulses to induce cell 
membrane permeability [192]. Recent advances have combined ultrasound gene therapy 
with microbubbles to increase transfer efficiencies [193]. The technique employs gas-
filled microbubbles stabilized with lipids, polymers, or proteins which stabilize the 
bubbles to allow for systemic administration. The target site is then exposed to ultrasound 
and when the microbubbles pass through the sonic cone, they oscillate, and cavitate, 
releasing their cargo at a high velocity and disrupting cell membranes. Ultrasonic gene 
delivery systems are more versatile and practical than their electroporation counterparts, 
but still require a solid tissue target site that is accessible via probe [194]. 
2.8.2.4 Hydrodynamic Gene Delivery 
Hydrodynamic gene transfer was first reported in vivo in 1999 [185]. Gene 
transfer by this method is achieved by injecting a very large volume of a DNA-containing 
solution into the tail vein of small rodents. The process of injecting a large volume 
(usually 8–12% of body weight) over a short period of time (3–5 seconds) causes the 
endothelial lining of the cardiovascular system to leak, allowing the DNA to penetrate 
into the tissue [195]. Hydrodynamic gene transfer allows for fast and easy transfection of 
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highly perfused organs such as the liver, kidney, lungs, and heart, but is limited to rodent 
models. The process of scaling this technique up to the volumes required to achieve the 
same effect in humans is not feasible. However, advances using catheters to perform 
local hydrodynamic gene transfer have been made, allowing for this technique to be used 
in large animals [196]. 
2.8.2.5 Gene Gun Delivery 
Finally, the last physical nonviral gene delivery method commonly utilized is 
gene transfer via gene gun. The gene gun system was first developed and used to 
transfect plants in 1987 [197]. Genetic material is coated onto metal particles such as 
gold, silver, or tungsten and the particles are delivered at a high velocity, powered by a 
compressed gas such as helium, into the target. This technique has been successfully used 
to deliver DNA to dermis, muscle, and tumor tissues and has even been used in five 
clinical trials on gene therapy to date [77]. 
2.8.3 Lipid-mediated Gene Delivery 
Transfer of genetic material using lipids was first accomplished in 1987 by 
Felgner et al. [198]. Of the nonviral methods, transfection using cationic lipids (i.e., 
lipofection) is the most popular and extensively studied, with thousands of publications 
examining hundreds of distinct variations of the basic shared lipid structure [199]. 
Cationic lipids used for gene delivery share three common features: a positively charged 
head group, a hydrophobic tail, and a linker region that joins the two regions together 
(Figure 2.3). 
Cationic lipids function by condensing polynucleotides through electrostatic 






Figure 2.3. The three domains of cationic lipids used in gene delivery: a hydrophobic tail 
and a hydrophilic head, joined by a linker. The above structure is that of 1,2-dioleoyloxy-




phosphodiester backbone of the DNA or RNA. The resultant tightly bound complex is 
termed a lipoplex and serves to protect the genetic cargo while aiding in cell penetration. 
Transfection efficiency and toxicity depend on a myriad of customizable factors, such as 
the composition of each of the hydrophilic and hydrophobic portions, and the DNA/lipid 
ratio. 
The most effective lipoplex formulations typically have a residual positive charge 
on the complex. This allows for association with cell membranes through interaction with 
the negatively charged membrane surface and causes the lipoplex to be endocytosed by 
the cell. In order to escape the endosomal compartment, it is hypothesized that the 
cationic lipids interact with anionic phospholipids in the wall of the endosome, 
facilitating concurrent disruption of the endosomal wall and dissociation of the 
polynucleotides from the lipids, releasing the cargo to the cell interior [200].  
Cationic lipoplexes are the most commonly used nonviral chemical transfection 
system in human trials. To date, they have been used in 111 clinical trials, composing 
5.9% of all gene therapy trials completed [77]. Limitations of cationic lipids for human 
therapy include the immune response they can elicit, acute toxicity, and the short duration 
of expression they mediate. Since cationic lipid lipoplexes form relatively loose 
complexes with DNA [201] with some externally exposed cargo [202], the patient’s 
immune system can recognize unmethylated CpG sequences from the plasmid DNA and 
mount a TLR9-mediated immune response increasing cytokine production [203]. 
Conjugation of polyethylene glycol (PEG) to cationic lipids has been shown to reduce 




2.8.4 Polymer Gene Delivery 
The other nonviral chemical method utilizes cationic polymers to mediate 
transfection and protect polynucleotides. Polycations are a particularly useful class of 
polymer for gene therapy. Similar to cationic lipids, these polymers form complexes with 
genetic material through electrostatic interactions between positively charged groups 
(usually amines) on the polymer and negatively charged phosphates on the nucleic acid 
backbone. 
These polymer:DNA complexes (termed polyplexes) mediate gene delivery 
primarily through bulk endocytosis into the cell; however, targeting moieties can be 
attached to increase cell specificity by receptor-mediated endocytosis. Once inside the 
endosomal compartment, most polyplexes employ an entirely different escape 
mechanism from the lipoplex escape mechanism, termed the “proton sponge effect” 
described below. An overview of polyplex entry mechanisms, endosomal escape, and 
DNA expression or siRNA knockdown can be seen in Figure 2.4. 
2.8.4.1 Polyethyleneimine Gene Delivery 
The polycation polyethyleneimine (PEI) was first shown to effect transfection of 
cells in 1995 by Boussif et al. [205] and is still used as a comparative benchmark in many 
experiments today. As a polymer, PEI demonstrated the unique ability to avoid lysosomal 
degradation by escaping from the endosome within cells. PEI can be synthesized as both 
a linear or branched polycationic polymer with primary, secondary, and tertiary amine 
groups in the ratio 1:2:1. The array of amine groups with their varying pKa values gives 
the polymer the ability to buffer over a wide range of pH values. At the physiological 








Figure 2.4. Overview of polyplex internalization, endosomal escape, DNA expression, and siRNA-mediated knockdown. 
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lowered to pH 5, such as that seen in the endosome, the degree of protonation more than 
doubles to 45% [206]. The “proton sponge effect” postulates that as protons are pumped 
into the endosome to lower the pH and aid in degradation, PEI and other cationic 
polymers buffer against the change, causing more protons and chloride counterions to be 
pumped in to lower the pH. Due to the much higher ionic strength within the endosome, 
water diffuses across the endosomal membrane via osmosis, causing the endosome to 
swell and rupture [206, 207]. The high concentration of counterions and the increased 
internal polymer electrostatic repulsions caused by the protonated amines is thought to 
help decomplex the polymer from the DNA/RNA cargo, releasing it to the 
cytoplasm [208, 209]. 
PEI comes in two common forms: branched and linear (Figure 2.5). Branched PEI 
(bPEI) is the most commonly used form for gene delivery due to its higher amine density 
and its wider buffering range. While the positive charge imbued by the amine groups is 
necessary for its DNA/RNA-complexation and endosomal-escaping functions, it also 
contributes to a high degree of toxicity seen when using PEI in vivo. The charged nature 
of the polymer leads to interaction with serum proteins, causing aggregation, and leads to 
unfavorable cell membrane destabilization [210]. Additionally, a great deal of PEI 
toxicity is due to its nondegradable nature [211]. 
Strategies to improve upon PEI transfection efficiencies while decreasing cellular 
toxicity include: synthesis of a novel acid-labile PEI (Figure 2.6) [212], conjugation with 
PEG to reduce toxicity [213], and linking low-molecular PEI via degradable or reducible 
bonds [214, 215]. Early work performed in our lab investigated conjugation of low-






Figure 2.5. The chemical structures of the prototypical cationic polymers linear 







Figure 2.6. Chemical structures of the degradable cationic polymers acid-labile 
polyethyleneimine (PEI), poly(4-hydroxyl-L-proline ester) (PHP), and poly[α-(4-
aminobutyl)-L-glycolic acid] (PAGA). Adapted from Kim et al. [212]. 
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to high molecular weight but severely decreased transfection efficiency, with cholesterol 
to form a water-soluble lipoprotein [216]. 
2.8.4.2 Poly-L-Lysine Gene Delivery 
Another common cationic polymer used for gene delivery is poly-L-lysine (PLL) 
(Figure 2.5). PLL acts as a cationic gene carrier due to its large number of ε-amino 
groups, allowing for electrostatic condensation and complexation of polynucleotides. 
This polymer was one of the first cationic polymers observed to demonstrate gene 
transfection capabilities [217]. However, its transfection efficiency is highly variable 
between cell types, and typically is not as high as that seen with other cationic polymers 
like PEI. Additionally, because the amine groups on PLL have much higher pKa values 
than other cationic polymers, it does not efficiently escape the endosomal compartment. 
To increase transfection efficiency with PLL, chloroquine (an endosomolytic agent) is 
often delivered with PLL [218, 219]. Unfortunately, the addition of chloroquine increases 
toxicity and is not feasible for in vivo applications. 
2.8.4.3 Degradable Polymers for Gene Delivery 
One of the major limitations of the early generation of cationic polymers was their 
nondegradability. Once the polymer carrier has penetrated and delivered its nucleic acid 
cargo inside of a cell, the inability of the cell to clear the polymer carrier results in 
delayed toxicity (7–9 hours after transfection) [211, 220]. To overcome this limitation in 
the early cationic polymers, carriers with degradable linkers were developed to allow the 
cell to break down the high molecular weight polymers into smaller fragments, aiding in 
their clearance and reducing their toxicity. Some of the major chemical moieties used to 
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allow for degradation of polymers include: hydrolyzable ester linkages, acid-labile imine 
linkers, and bioreducible disulfide linkages. 
The first degradable polymer developed for gene delivery was the polyester agent 
poly(4-hydroxy-L-proline ester) (PHP) (Figure 2.6). The polymer is degradable due the 
incorporation of hydrolyzable ester bonds as the monomer linker groups. The rate of 
hydrolysis of PHP is enhanced by the presence of the amine groups and the polymer is 
readily degradable, hydrolyzing in less than 24 hours [221]. Another early biodegradable 
polymer for gene delivery, poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) (Figure 2.6), 
was developed in this lab and was shown to a safe and nontoxic alternative to polymers 
such as PLL [222]. 
While polymers incorporating ester or other hydrolyzable bonds reduce delayed 
toxicity due to intracellular accumulation of polycation carriers and their resultant 
disruption of cellular function, the nonspecific nature of hydrolyzable bond degradation 
leads to limited circulatory and extracellular in vivo half-lives. In order to develop 
polymers with the ideal characteristics of resistance to degradation in the extracellular 
space, but which degrade inside the cell, releasing their cargo and allowing for clearance, 
polycationic polymers with reducible disulfide bonds were developed. 
2.8.4.4 Bioreducible Polymers for Gene Delivery 
 Disulfide bonds are an attractive linker for polymeric gene carriers due to their 
stability in extracellular environments, but their susceptibility to reduction in the 
intracellular, particularly cytoplasmic, space through thiol-disulfide exchange [223, 224]. 
Many proteins, especially those which are secreted, form disulfide bonds between 
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cysteine residues as a way to lend stability to the protein, aid in protein folding, and 
maintain the folded structure. 
Exposed disulfide bonds are particularly susceptible to reduction in the cytoplasm 
due to the high concentration of the thiol-containing molecule glutathione. The cytoplasm 
is a highly reductive environment, owing to a high concentration of glutathione (0.5–
10 mM intracellular versus 15 µM extracellular) [225-227], and because the cytoplasm 
maintains a ratio of reduced glutathione/oxidized glutathione disulfide (GSH/GSSG) of 
up to 100/1 [228]. The reduced glutathione pool is maintained through the action of the 
NADH-dependent flavoenzyme glutathione reductase to convert GSSG back to the 
reduced GSH form to maintain the reductive gradient. Glutathione stores are also 
maintained by synthesis of new glutathione from glutamate, cysteine, and glycine by 
γ-glutamylsynthetase followed by glutathione synthetase. When GSH levels are high, 
glutathione reduces disulfide bonds via thiol-disulfide exchange. In this reaction, the 
thiolate anion on GSH attacks a sulfur atom contained in a disulfide bond. The primary 
disulfide bond is broken and a new disulfide bond between glutathione and the attacked 
sulfur group is formed [223]. 
Due to the large difference between intracellular and extracellular glutathione 
levels, disulfide bonds have proven to be excellent linkers in gene delivery polymers, 
imbuing stability in the circulation and extracellular milieu while rapidly degrading once 
the polymer is internalized to the cytoplasm. This results in increased transfection 
efficiencies, with decreased toxicity and cellular accumulation. 
The first disulfide-containing polymer used for gene delivery was a disulfide-
linked PEI [229]. Gosselin et al. found that their disulfide-crosslinked PEI significantly 
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increased transfection efficiency in Chinese hamster ovary cells compared to the 
nonreducible parent low molecular weight PEI. The levels of transfection were almost 
equivalent to that seen with 25 kDa bPEI. Other groups investigated different disulfide 
cross-linkers to form bioreducible PEI and also found transfection efficiencies similar to 
25 kDa bPEI with decreased or very similar cytotoxicities [215, 230]. 
Other classes of bioreducible polymers beyond disulfide-linked PEI have also 
been synthesized and include disulfide poly(amido amine)s (SS-PAAs), and poly(ß-
amino ester)s (Figure 2.7). SS-PAAs employ Michael addition-type reactions between 
primary amines and cystamine bisacrylamide. Some of the first polymers synthesized 
from this family demonstrated that they can condense nucleic acids to positively charged 
and nano-sized polyplexes (+20 mV ζ-potential and <200 nm, respectively) [231, 232]. 
These SS-PAAs also demonstrated greater buffering capabilities than even the amine-rich 
PEI polymers, aiding in escape from the endosomal compartment via the proton sponge 
effect. SS-PAAs are also capable of highly efficient transfection even in the presence of 
serum with little cytotoxicity even at high polymer:nucleic acid weight ratios [232]. 
Finally, many SS-PAAs contain pendant amine groups that are amenable to modification, 
allowing grafting of targeting moieties to the polymer. 
2.8.5 Targeted Polymer Gene Carriers 
In order to enhance the efficiency and especially specificity of polymer gene 
carriers for target cells, targeting groups can be attached to the carrier. Nontargeting 
polymer gene carriers interact nonspecifically with cells through interaction with 
negatively charged surface molecules like glycosaminoglycans and enter the cell via 






Figure 2.7. Bioreducible poly(amido amines) based on cystamine bisacrylamide. 
DAH = diaminohexane, TETA = triethylenetetramine, EDA = ethylene diamine 
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are bound by serum proteins, resulting in rapid clearance by the reticuloendothelial 
system (RES) [235]. Conjugation of shielding moieties such as PEG have been shown to 
increase circulatory half-life, but decrease transfection efficiency by interfering with cell 
surface interaction, and do not increase target cell specificity [236, 237]. 
To allow polyplexes to selectively transfect specific cell types, a variety of 
functional groups and targeting moieties can be conjugated to the polymer, including 
peptides, sugars, antibodies/antibody fragments, and proteins [238]. The specific 
interaction of these targeting groups with cell membrane components leads to receptor-
mediated endocytosis, allowing polyplex entry to the cell [239]. By combining targeting 
ligand polymer conjugation to increase target cell uptake with PEG shielding to reduce 
nonspecific cellular interactions, polymers with high tissue specificity and transfection 
efficiency can be synthesized. 
2.9 Cell Therapy for Cardiovascular Disease 
With the surge of interest in stem cells as a therapeutic strategy in the late 1990s, 
it was not long before attempts were made to apply stem cell therapy to MI. Since the 
loss of viable tissue in the ischemic region after myocardial infarction has long been 
known to decrease the functionality of the myocardium, the potential for stem cells to 
repopulate the heart and form contractile cardiomyocytes was quickly 
investigated [240, 241]. 
A variety of cell sources have been used in studies of cell therapy for ischemic 
heart disease, but they can be classified as allogeneic (from another donor) or autologous 
(from the patient). The earliest studies evaluating stem cells for cardiac repair used 
allogeneic stem cells such as embryonic stem cells, which were also one of the first stem 
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cell populations discovered. As the research around stem cell classes advanced, more 
populations of stem cells were discovered and evaluated for cardiac repair (Table 2.4). 
2.9.1 Mesenchymal Stem Cells 
Adult mesenchymal stem cells are most commonly derived from bone marrow or 
adipose tissue. In the area of cardiac cell therapy, however, bone marrow-derived 
mesenchymal stem cells have been the most thoroughly investigated. Mesenchymal stem 
cells are multipotent in nature, differentiating to cardiomyocytes, adipocytes, osteoblasts, 
chondrocytes, and many other cell types, though not as many as pluripotent stem 
cells [243, 244]. 
One of the reasons for the intense interest of using mesenchymal and other bone 
marrow-derived stem cells for cardiac therapy is the ease of obtaining the cells from bone 
marrow aspirates. Stem cells can rapidly be isolated from bone marrow and quickly 
expanded to a sufficient number to allow for autologous donation. Though autologous 
therapy is relatively simple with this stem cell lineage, mesenchymal stem cells are less 
immunogenic than other cell types, making allogeneic cell therapy a possibility [245]. 
Allogeneic therapy eliminates or greatly reduces the delay necessary when autologous 
cells are isolated, expanded, and prepared for implantation. 
Mesenchymal stem cells, while capable of differentiating to cardiomyocytes, 
appear to do so only at a very low rate when injected in vivo [245, 246]. While this limits 
the repopulation of the myocardium with functional cardiomyocytes, implanted 
mesenchymal stem cells have been shown to have a positive effect on resident cells 
through the secretion of paracrine growth factors [243, 247]. 
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Table 2.4 Cell Types Investigated for Cardiac Repair 
 
 
Allogenic Stem Cells Autologous Stem Cells 
Embryonic stem cells Cardiac stem cells 
Fetal cardiomyocytes Adipose-derived stem cells 
Human umbilical cord-derived stem cells Skeletal myoblasts 
 Bone marrow-derived stem cells 
 Mononuclear/CD34+ fraction 
 Mesenchymal stem cells 
 Endothelial progenitor cells 
 Multipotent adult progenitor cells 
 Induced pluripotent stem cells 
 
 
Adapted from Mozid et al. [242]. 
59 
 
2.9.2 Cardiac Stem Cells 
The heart has long been viewed as a static organ, with little to no cardiomyocyte 
turnover. Recently, however, this view has been disproven with the discovery of resident 
populations of cardiac stem cells (CSCs) within the myocardium [248]. While these cells 
make up less than 2% of the total cells within the myocardium, they have been shown to 
contribute to the growth of new cardiomyocytes [249, 250] and coronary vessels [249], 
especially during pathological states [248, 251]. Importantly, these resident stem cells 
have demonstrated they play a role in regeneration of cardiomyocytes and vascular cells 
after myocardial infarction [249]. 
Despite their low population levels within the myocardium, CSCs can be 
harvested from patients, proliferated ex vivo, and used for autologous implantation [252]. 
At least two clinical trials evaluating CSCs in human patients suffering from ischemic 
cardiomyopathy [253] and MI [254] have been completed with encouraging results. Cells 
were delivered by intracoronary infusion and in both trials provided improvement in 
infarct size and LV function. 
While CSCs have shown promising results thus far, because the field is still 
nascent, they are still one of the least studied stem cells for cardiac repair. Little is known 
about their long-term fate in the heart and if the positive results seen in short-term studies 
will vary over to the long term. 
2.9.3 Embryonic Stem Cells 
Human embryonic stem cells were first isolated in 1998 and are a pluripotent 
stem cell capable of differentiating into almost all cell lineages [255]. Importantly for use 
in cardiac cell therapy, embryonic stem cells have been shown to differentiate into 
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contracting cardiomyocytes [256, 257]. The use of embryonic stem cells is still the source 
of passionate ethical debate due to their source with the resulting regulatory restrictions 
limiting their adoption.  
While embryonic stem cells have often been considered the gold standard source 
for stem cell therapy, their use is not without limitations. Since embryonic stem cells are 
derived from allogenic sources, they can trigger immunogenicity in the recipient [258]. 
Additionally, embryonic stem cells have shown predisposition to form teratomas when 
they are injected in vivo [259]. Finally, while embryonic stem cells are known to 
differentiate to cardiomyocytes, there is some debate whether the stem cells implant with 
sufficient structural and electromechanical efficiency to contribute to functional recovery 
of the myocardium [260].  
2.9.4 Skeletal Myoblasts 
Skeletal myoblasts are not true stem cells as they are limited in their ability to 
differentiate past a myocyte fate. They are derived from skeletal muscle satellite cells that 
normally are located under the basal membrane in a quiescent state [261]. When injury 
occurs, the satellite cells mobilize, proliferate, and fuse to existing muscle cells in order 
to regenerate muscle tissue. Skeletal myoblasts are satellite cells that are in the process of 
proliferating but have not yet fused with skeletal myocytes. 
Skeletal myoblasts were one of the first cell populations considered for cardiac 
repair because of several clinically attractive attributes they possess. Some of these 
attributes that make them an ideal cell source for cardiac cell therapy include: a high 
resistance to hypoxia [262]; ease of isolation [242, 263]; rapid expansion capabilities (a 
small biopsy can provide over one billion cells in a 2–3 week time period and the process 
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can be automated) [264]; and finally, since they are easily derived from an autologous 
origin, they do not provoke an immune response [265]. Additionally, the limited 
differentiation capabilities of skeletal myoblasts may be considered a limitation as they 
do not directly transdifferentiate to cardiomyocytes [266], but it is also a benefit since 
there is no risk of teratoma formation. 
Even though skeletal myoblasts do not directly differentiate to cardiomyocytes, 
experimental studies in both small and large animal studies have shown they can be 
successfully implanted to ischemic hearts to provide functional left ventricular 
benefit [267-272]. 
Early uncontrolled human trials evaluating the therapeutic benefit of skeletal 
myoblast implantation in chronic heart failure patients showed promising results in the 
form of improved global and regional contractility, and cell viability [273-276]. 
However, subsequent expanded and controlled human clinical trials have produced more 
mixed results. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) 
trial was a multicenter, controlled, randomized, and double-blinded Phase II trial 
evaluating autologous skeletal myoblasts. Cells were expanded ex vivo for 3 weeks then 
implanted intramyocardially to the ischemic border zone during bypass surgery. 
Unfortunately, in this trial, there was no significant improvement in the primary 
endpoints of global and regional LV function [277]. The longest trial of the impact of 
skeletal myoblast implantation for cardiac repair comes from Dib et al. In a 
nonrandomized, uncontrolled Phase I trial, patients showed improvements in LV ejection 
fraction and myocardial viability with no observed adverse consequences of skeletal 
myoblast therapy 4 years after implantation [278, 279]. Additionally, histological 
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analysis of implanted skeletal myoblasts in humans has shown that the cells form striated 
myotubes in the scar area and engraft in-line with endogenous 
cardiomyocytes [278, 280].  
There was initially some concern as implantation of skeletal myoblasts to the 
heart was reported to increase the risk of arrhythmias [273, 275, 279, 280]. However, the 
MAGIC trial did not observe any significant increase in arrhythmias in patients receiving 
skeletal myoblasts but did note a trend toward significance [277]. In response to the 
proarrythmogenic concerns of skeletal myoblasts, Chachques et al. hypothesized that the 
arrythmogenicity of the cells was due to an inflammatory and antigenic response against 
the fetal bovine serum used to expand the isolated cells. In a study to test this hypothesis, 
isolated cells were expanded using serum derived from the donor. This study detected no 
incidence of arrhythmias over a 1–2 year period [281]. 
Our lab has demonstrated previously that primary skeletal myoblasts transfected 
with a human isoform of VEGF165 express and secrete high levels of VEGF for up to one 
week [282] and that these cells promote angiogenesis in vivo as reported in Chapter 3 of 
this dissertation [283]. 
2.9.5 Induced Pluripotent Stem Cells 
In light of the recent awarding of the 2012 Nobel Prize in Physiology or Medicine 
jointly to John B. Gurdon and Shinya Yamanaka for the discovery that differentiated cells 
can be reprogrammed to become pluripotent stem cells [284, 285], a brief overview of 
recent advances applying this technology to MI is warranted. Induced pluripotent stem 
cells (iPSCs) are still most commonly derived from a fibroblast cell source, which can be 
harvested from an autologous skin biopsy. Once dedifferentiated to a pluripotent state, 
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iPSCs can be differentiated to a cardiomyocyte fate [286, 287]. Murine and porcine 
studies have shown that iPSCs administered to the heart improve cardiac function and 
attenuate LV remodeling [288, 289]. 
While the investigation of iPSC use for myocardial repair is still in its infant 
stages, they have great potential for cardiovascular applications. iPSCs can be generated 
from donor biopsies and have excellent differentiation capabilities. However, limitations 
include rapid teratoma formation and the time required (over 30 days) to generate 
replicating iPSCs from fibroblasts. 
2.10 Therapeutic Angiogenesis 
Therapeutic angiogenesis refers to the treatment strategy of establishing new 
vasculature to cells and tissues that are not adequately served by the circulatory system 
[290]. Over the years, more clinical success in blocking angiogenesis in the cases of 
cancer and ocular diseases have been achieved, but a great deal of research is being 
performed investigating the potential benefit of establishing blood supply to ischemic 
tissue. The formation of new vessels, whether arterial or venous in nature, is a complex 
physiological process and is mediated by several large families of proteins that promote 
directed vessel growth and vessel maturation. Some of the major families with 
therapeutic applications include the VEGF, PDGF, and FGF families. 
2.10.1 VEGF 
The most popular family of angiogenic factors for establishing new blood vessels 
is the vascular endothelial growth factor (VEGF) family. The mammalian VEGF family 
consists of 7 factors, VEGF-A, -B, -C, -D, -E, -F, and placental growth factor (PIGF). All 
members of the VEGF family produce their action by interacting with the tyrosine kinase 
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receptors VEGFR-1/Flt1, VEGFR-2/Flk1/KDR, and VEGFR-3/Flt2. These receptors are 
found in high abundance on the surface of endothelial cells. VEGF-A is the most active 
family member and stimulates vessel growth by signaling through VEGFR-2 [291]. 
VEGF-A is known to be one of the most important angiogenic forms of VEGF and 
VEGF-A deficiency on even one allele is embryonically lethal, showing severely 
abnormal blood vessel development [292]. VEGF-A has five isoforms containing 121, 
145, 165, 189, or 206 amino acids. Of the five isoforms, VEGF165 is the most promising 
candidate for therapeutic use due to its ability to create the necessary growth factor 
gradients needed for efficient and functional vessel growth, and because it is 100× more 
potent than VEGF121 [293]. 
VEGF165 acts through interaction with the VEGFR-1 and VEGFR-2 receptors to 
stimulate endothelial cell growth and vessel sprouting. Endothelial tip cells sense the 
levels of VEGF-A and rapidly guide capillary migration towards the source of VEGF-A 
expression [294]. 
2.10.2 Other Angiogenic Factors 
Two additional proangiogenic factors investigated for therapeutic vessel growth 
are platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF). The 
PDGF family plays an important role in angiogenesis but aids more in the maturation of 
vessels, allowing them to function properly than in their initial formation [295]. The 
PDGF growth factors help recruit pericytes to budding and growing vessels [296, 297]. 
Without proper pericyte recruitment, the formed vessels are immature, leaky, display a 
high degree of tortuosity, decreased perfusion, and do not always remain viable after 
angiogenic therapy has ceased [298, 299]. Due to the important role PDGF plays in 
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producing highly functional vessels, PDGF therapy is often paired with VEGF therapy, 
combining the potency of VEGF at stimulating rapid vessel formation, with PDGF to 
convert the newly formed vessels into stable and mature vessels [300, 301]. 
FGF is another family of angiogenic proteins with 23 members and similar 
function as the VEGF family. The FGF proteins promote angiogenesis by interacting 
with 4 unique cell membrane-bound tyrosine kinase receptors [302]. Unlike VEGF, FGF 
receptors are expressed on many different cell types, including smooth muscle cells and 
fibroblasts, and can act on these cells causing them to secrete additional angiogenic 
factors [303]. Heart studies have shown that FGF signaling induces hedgehog, 
angiopoietin-2 (ANG-2), and VEGF-B release, and aids in supporting long-term vascular 
integrity [304]. Initial testing of FGF in the Angiogenic Gene Therapy (AGENT1) trial 
showed improved exercise tolerability in patients after 4 weeks [305]. However, the 
followup study in the AGENT 3/4 trial was prematurely interrupted as the study was not 
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BIOREDUCIBLE POLYMER-TRANSFECTED SKELETAL 
 








Implantation of skeletal myoblasts to the heart has been investigated as a means to 
regenerate and protect the myocardium from damage after myocardial infarction. While 
several animal studies utilizing skeletal myoblasts have reported positive findings, results 
from clinical studies have been mixed. In this study we utilize a newly developed 
bioreducible polymer system to transfect skeletal myoblasts with a plasmid encoding 
vascular endothelial growth factor (VEGF) prior to implantation into acutely ischemic 
myocardium. VEGF has been demonstrated to promote revascularization of the 
myocardium following myocardial infarction. We report that implanting VEGF 
expressing skeletal myoblasts into acutely ischemic myocardium produces superior 
results compared to implantation of untransfected skeletal myoblasts. Skeletal myoblasts 
expressing secreted VEGF were able to restore cardiac function to nondiseased levels as 
measured by ejection fraction, to limit remodeling of the heart chamber as measured by 
                                                 
1
 Reprinted from Biomaterials, 32/3, A.N. McGinn, H.Y. Nam, M. Ou, N. Hu, C.M. 
Straub, J.W. Yockman, D.A. Bull, S.W. Kim, Bioreducible polymer-transfected skeletal 
myoblasts for VEGF delivery to acutely ischemic myocardium, 942-949, (2011), with 
permission from Elsevier. 
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end systolic and diastolic volumes, and to prevent myocardial wall thinning. 
Additionally, arteriole and capillary formation, retention of viable cardiomyocytes, and 
prevention of apoptosis was significantly improved by VEGF expressing skeletal 
myoblasts compared to untransfected myoblasts. This work demonstrates the feasibility 
of using bioreducible cationic polymers to create engineered skeletal myoblasts to treat 
acutely ischemic myocardium. 
3.2 Introduction 
Myocardial infarction (MI) is the leading cause of death in developed nations and 
one of the most common causes of death in the world. Unfortunately, current 
pharmacological treatment regimens for myocardial infarction do not reliably limit 
remodeling of the left ventricle (LV) postinfarction and prevent progression to heart 
failure. Novel potential treatments, including gene and cell therapies, offer a means to 
directly treat the pathophysiology underlying the long-term complications of myocardial 
infarction—loss of cardiomyocytes due to necrosis and apoptosis. 
Implantation of cells to the myocardium has long been investigated as a means to 
recover myocardial tissue and improve outcomes post-MI. Skeletal myoblasts are a class 
of progenitor muscle cells that may recover infarcted myocardium and limit remodeling 
of the left [1-3] and the right ventricle [4]. Several studies have demonstrated the ability 
of skeletal myoblasts to regenerate myocardium through mechanisms including in situ 
proliferation and fusion with resident myotubes and myofibers [5, 6]. While initial results 
using skeletal myoblasts for implantation to the myocardium have been positive, the 
long-term benefits remain uncertain. Implantation of cells is limited by the rapid loss of 
cells from the injection site. With the majority of cells being lost by mechanical means 
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soon after injection, the primary benefit of skeletal myoblast implantation is thought to 
derive from the paracrine effects of the growth factors and cytokines secreted by the 
injected cells [7, 8]. 
In addition to cell-based approaches, other investigators have focused on 
angiogenic therapies to treat myocardial infarction. Therapies using angiogenic factors, 
such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor 
(bFGF), have demonstrated the beneficial effects of angiogenesis on protection of 
endogenous cardiomyocytes and on the retention of functionally contractile myocardium 
[9-11]. The most common technique for expressing angiogenic factors has been the 
utilization of viral vectors to deliver VEGF into endogenous cardiomyocytes [12]. In 
addition to direct transduction of myocardial tissue, examples of viral transduction of 
skeletal myoblasts have been published [13-15]. While viral gene therapy offers high 
transfection efficiencies, its clinical utility is limited by host immune responses, 
oncogenic potential, limitations in viral loading, and difficulty in large-scale 
manufacturing. For these reasons, the development of safer, nonviral methods for gene 
delivery is increasingly important. 
Nonviral polymer gene therapy is a technique that has been rapidly advancing 
over the past 10 years. Polymer gene carriers are nonimmunogenic, stable, have a large 
DNA loading capacity and are also easily manufactured. They are, however, when 
compared to viral vectors, less efficient at transfecting cells and producing prolonged 
gene expression. Among cationic polymers for gene therapy, polyethyleneimine (PEI) 
has recently been used to transfect human skeletal myoblasts with VEGF for implantation 
into the myocardium for cardiac repair following myocardial infarction [16]. While PEI 
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has long been considered the gold standard for polymer transfection, it is known to be 
highly toxic to most cell types and it lacks the ability to rapidly release its DNA cargo 
upon internalization to the cell. We have recently reported the synthesis and validation of 
disulfide-containing bioreducible polymers which improve upon PEI by allowing for the 
rapid release of DNA cargo upon internalization to the cell. These newly described 
polymers, poly(cystaminebisacrylamide-diaminohexane) [poly(CBA-DAH)] and 
poly(cystaminebisacrylamide-diaminohexane-arginine) [poly(CBA-DAH-R)], showed 
11- and 16-fold higher expression of luciferase, respectively, with significantly less 
toxicity than branched PEI. We have also demonstrated that these polymers can 
efficiently transfect the functional gene VEGF165, the predominant isoform of VEGF 
which possesses high angiogenic potency, into primary myoblasts [17]. The production 
of therapeutic levels of secreted VEGF by these transfected skeletal myoblasts suggests 
that transfected primary skeletal myoblasts can be used as bioreactors for angiogenic 
VEGF expression in vivo [17]. 
In this study, we utilized an in vivo animal model to evaluate the therapeutic 
efficacy of polymer-transfected primary skeletal myoblasts in limiting the size of 
myocardial infarction. Rats were treated with skeletal myoblasts that had been transfected 
with poly(CBA-DAH) containing a plasmid encoding human VEGF165. These VEGF165-
expressing skeletal myoblast-treated animals were compared to: 1) treatment with 
untransfected myoblasts; 2) no treatment (ligation only); and 3) thoracotomy only. 
Magnetic resonance imaging (MRI), histology and immuno-histochemistry were used to 
determine differences in cardiac function, infarct size, arteriole and/or capillary density, 
and apoptosis between the study groups. 
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3.3 Materials and Methods 
All experiments were approved by the University of Utah’s Institutional Animal 
Care and Use Committee and followed the guidelines provided by the National Institutes 
of Health in Guide for the Care and Use of Laboratory Animals. 
3.3.1 Isolation, Culture and Characterization of Rat Primary Skeletal Myoblasts 
The process of isolating, culturing and characterizing rat skeletal primary 
myoblasts was reported in our previous work [17] with slight modifications from 
published protocols [18, 19]. 
Briefly, rat skeletal primary myoblasts were obtained from young rat hindlimbs. 
Isolated rat skeletal primary myoblasts were maintained in growth medium consisting of 
Ham’s F-10 supplemented with 20% FBS, 2.5 ng/ml human bFGF, penicillin 
(200 μg/ml), and streptomycin (200 μg/ml) and incubated at 37 °C in 5% CO2. Primary 
cultures derived from skeletal muscle consisting of myoblasts and fibroblasts were 
incubated in Ham’s F-10 medium, giving a growth advantage to myoblasts over 
fibroblasts. Primary myoblasts were separated from contaminating cells, such as 
fibroblasts, by taking advantage of their differential adherence to the flask over several 
passages. After two weeks of selective growth, cells were trypsinized, suspended in 90% 
serum and 10% dimethyl sulfoxide (DMSO) and frozen in liquid nitrogen. 
To select the primary myoblasts, cells were immunostained using the primary 
antibody (mouse-anti-human desmin IgG1/) and the secondary antibody (Streptavidin-
horseradish peroxidase, SAv-HRP conjugated biotinylated anti-mouse IgG), fixed by 2% 
paraformaldehyde in PBS for 30 minutes, washed with PBS and then with blocking 
buffer (3% BSA with 0.5% Triton X-100 in PBS) for 1 hour at room temperature. The 
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samples were incubated with 1:100 primary anti-desmin IgG at 4 °C overnight. The next 
day, cells were washed with PBS, diluted in secondary antibody (1:100 biotinylated anti-
mouse IgG) for 1 hour at room temperature, and washed three times in PBS. SAv-HRP 
was applied and the samples were incubated for 30 minutes at room temperature. DAB 
substrate solution was applied to the slides and incubated until the desired color intensity 
was reached (around 5 minutes). The cells were dehydrated using 95% alcohol and 
xylene and covered with Fluoromount
 TM 
Mount Gel (Sigma-Aldrich, St. Louis, MO). 
After several weeks in culture, the vast majority of the cells stained positive for the 
myoblast specific protein desmin. 
3.3.2 Preparation of Polymer, Poly(CBA-DAH), and Plasmid, pCMV-VEGF165 
The poly(disulfide amine) polymer, poly(CBA-DAH), was synthesized as detailed 
previously [20]. Briefly, poly(CBA-DAH) was synthesized by Michael reaction of 
N-Boc-DAH and CBA in MeOH/H2O solution (9:1, v/v) and the reaction was protected 
from light under nitrogen at 60 °C for 3 days with stirring. After the third day, 10% molar 
ratio of N-Boc-DAH was added to the reaction mixture to consume any unreacted 
acrylamide functional groups and the reaction was allowed to proceed for an additional 
2 hours. The reaction products were precipitated with anhydrous diethyl ether followed 
by deprotection of the N-Boc groups with the reagent solution 
(TFA:triisobutylsilane:H2O , 95:2.5:2.5, v/v) in an ice bath for 30 minutes. The crude 
product was again precipitated with anhydrous diethyl ether and dried under vacuum. The 
final product was dialyzed against deionized water overnight (MWCO=1000 Da, 
Spectrum Laboratories, Inc., Rancho Dominguez, CA), and lyophilized to obtain 
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poly(CBA-DAH). The poly(CBA-DAH) was analyzed by 
1
H NMR (400 MHz, D2O) to 
confirm successful synthesis of the desired product.  
The plasmid, pCMV-VEGF165, containing the vascular endothelial growth factor 
gene 165 was amplified in E. coli DH5α cells and purified by standard Maxiprep kit 
(Invitrogen, Carlsbad, CA). 
3.3.3 Rat Myocardial Infarction Model 
Male Sprague-Dawley rats were anesthetized under 4% isoflurane for induction, 
intubated and kept under 2% isoflurane for maintenance of anesthesia. The left chest was 




 intercostal space, exposing the 
heart. The left anterior descending coronary artery (LAD) was permanently ligated using 
a single stitch of 6-0 prolene suture (Ethicon). After confirming successful ligation of the 
LAD by observation of visible blanching of the left ventricle, the animals were assigned 
to one of three treatment groups: 1) Ligation only (n = 7), 2) injection of untreated 
skeletal myoblasts (n = 7), and 3) injection of VEGF165-transfected skeletal myoblasts 
(n = 7). Animals assigned to cell injection groups received 2 × 10
6
 cells in 200 µl PBS in 
three separate injections to the border zone of the infarct. After the injection of cells, the 
chest was closed in layers and the animal was allowed to recover under a warming lamp. 
Additionally, some animals received a full thoracotomy with exposure of the heart, but 
no ligation of the LAD to act as sham operation controls (n = 5). 
Primary myoblasts were transfected with poly(CBA-DAH)/pCMV-VEGF165 at 
the ratio of 20:1 (w/w) 24 hours prior to the surgery. Cells were injected at the border 
zone of the infarct with three injections for a total number of cells ~2 × 10
6
/200 µl in 
PBS. 
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3.3.4 VEGF Expression Study 
To verify expression of VEGF in the heart following injection of VEGF-
transfected myoblasts into the myocardium, VEGF levels were measured three days after 
surgery using a commercially available human VEGF165 ELISA kit (R&D Systems, 
Minneapolis, MN). A total of eight animals were treated with myoblasts transfected with 
VEGF, eight animals were treated with untransfected myoblasts, while eight control 
animals received no myoblasts and underwent ligation only. Hearts were weighed, and 
homogenized in 1× TE buffer containing protease inhibitors. 100 µl of the supernatant 
was used for determination of VEGF levels by ELISA assay.  
The quantification of VEGF protein was determined using a UV absorbance plate 
reader (Model 680, Bio-Rad Lab, Hercules, CA). All experiments were performed in 
triplicate and quantitated using the supplied VEGF standard. 
3.3.5 Magnetic Resonance Imaging (MRI) 
Magnetic resonance imaging (MRI) was performed to determine changes in 
indices of heart function in all animals. Four weeks following surgery, the animals were 
analyzed by cardiac MRI to measure parameters of heart function. Anesthesia induction 
was achieved in each animal by exposure to 4% isoflurane and maintained with 2% 
isoflurane. The rats were placed prone on a pressure sensor to measure respiration, and a 
pulse oximeter was attached to the rat’s foot. The heart was imaged using a Bruker 
Biospec 7T/30 cm system operated with Bruker AVANCE II electronics (Bruker BioSpin 
MRI GmbH, Ettlingen, Germany). A Bruker birdcage quadrature resonator (72 mm inner 
diameter) was used for signal transmission and reception (Bruker BioSpin MRI GmbH, 
Ettlingen, Germany). The images were acquired using black blood FLASH CINE 
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parameters with double-gating off respiration and ECG. The instrument settings were as 
follows: repetition time (TR) = 31 ms, echo time (TE) = 2.8 ms, number of averages 
(NEX) = 4, field of view (FOV) = 8 cm × 8 cm, in-plane resolution = 408 × 312 µm, slice 
thickness = 2 mm, number of movie frames = 5. Prospective gating was achieved using 
SAII monitoring and gating systems (SA Instruments, Stony Brook, NY, USA). 
Resultant CINE MRI sequences were analyzed for left ventricular ejection 
fraction, wall thickness, and volume using the freely available software Segment v1.8 
(Segment; http://segment.heiberg.se) [21]. The left ventricle was analyzed in a semi-
automated manner by an investigator blinded to the treatment groups. Wall thickness was 
measured at the mid-ventricular level in a short-axis view at end diastole and end systole. 
Measurements of left ventricle end diastolic and end systolic volume were calculated 
from one 2 mm slice at the height of the base of the papillary muscles in order to 
normalize across groups. 
3.3.6 Histology and Immunohistochemistry 
The day after MRI, rats were sacrificed by overdose of isoflurane gas inhalation. 
The hearts were excised, perfused with 20 ml of Heparin-PBS, 20 ml of 2.56 M KCl, 
20 ml of 10% formalin, and fixed in 10% formalin at 4 °C till sectioning. Hearts were 
sectioned sagittally via the LV into 4 µm sections. Immunohistochemical staining was 
performed on the sections of formalin-fixed, paraffin-embedded tissue. Sections were air-
dried at room temperature and then placed in a 60 °C oven for 30 minutes to melt the 
paraffin. All of the staining steps were performed at 37 °C using an automated 
immunostainer (BenchMark® XT, Ventana Medical Systems, Tucson, AZ). 
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Collagen in the heart sections was stained using Masson’s trichrome. The infarct 
size of myocardium was calculated by the total infarction area divided by the total LV 
area using a Zeiss Stemi 2000-C Stereo Microscope (Edmund Optics Inc. Barrington, NJ, 
USA). To evaluate the arteriolar and capillary density and the loss of cardiomyocytes 
with the myocardial infarction, heart sections were immunohistochemically stained using 
α-smooth muscle actin, endocardial cell specific CD31 (Purified Mouse Anti-Rat CD31, 
Abcam), and cardiomyocyte specific cTnT (Monoclonal Anti-Troponin T antibody, 
Sigma). The sections were detected using the IView DAB detection kit-research (Ventana 
Medical Systems), which is an open secondary, Streptavidin-HRP system, utilizing DAB 
(3-3' diaminobenzidine) as the chromogen. The sections were counterstained with 
hematoxylin (Ventana Medical Systems) for 4 minutes. 
Capillaries positive for CD31 and α-smooth muscle actin-positive arterioles over 
the infarcted region were counted in five random high power fields (hpf) per specimen as 
the average number of capillaries per field (Nikon Eclipse TE300 Microscope). Arterioles 
were defined as vessels with an internal diameter of <50 μm; vessels with a diameter of 
<10 μm were considered capillaries. The loss or recovery of cardiomyocytes by cTnT 
staining was determined throughout the border zone of five hpf per specimen. The 
determination of apoptosis was performed using a commercially available kit (ApopTag 
Apoptosis Detection Kit, Intergen). Apoptosis in the infarcted regions was examined in 
five random hpf per section. For all the histology, every hpf was randomly chosen within 
the infarct border zone by an investigator blinded to the treatment groups. Analysis of all 
images was carried out with NIH ImageJ software (NIH, Bethesda, MD). 
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3.3.7 Statistical Analysis 
Results are expressed as the mean value ± standard error of the mean (SEM). 
Differences between groups were identified by one-way analysis of variance (ANOVA) 
followed by Tukey post hoc analysis to identify significance between groups using 
GraphPad Prizm 4.03 software (GraphPad Software, La Jolla, CA). Statistical shorthand 
of P < 0.05, P < 0.01, and P < 0.001 are indicated as *, **, and ***, respectively, 
throughout the manuscript figures. 
3.4 Results 
An acute myocardial infarction (MI) model was used to evaluate the therapeutic 
efficacy of VEGF-transfected skeletal primary myoblasts. Myocardial infarction in 
Sprague-Dawley rats was induced by ligation of the left anterior descending coronary 
(LAD) artery as previously described [22]. Animals were randomly placed into one of 
four groups: thoracotomy only (n = 5 short-term study, n = 5 long-term study), 
thoracotomy followed by ligation only (n = 5 short-term study, n = 7 long-term study), 
thoracotomy with ligation followed by injection of primary untransfected myoblasts 
(n = 5 short-term study, n = 7 long-term study), and thoracotomy with ligation followed 
by injection with primary myoblasts transfected with poly(CBA-DAH)/pCMV-VEGF165 
(n = 5 short-term study, n = 7 long-term study). The primary myoblasts were transfected 
with poly(CBA-DAH)/pCMV-VEGF165 at a 20:1 w/w ratio 24 hours before surgery and 
the transfected cells were injected at the border zone of the infarction. Our previously 
published results have demonstrated the efficacy of this approach in successfully 
transfecting primary myoblasts and achieving sustained VEGF expression and 
secretion [17]. 
104 
3.4.1 Short-Term VEGF Expression Study 
To determine whether transfected primary myoblast transplantation affected 
VEGF expression, the levels of VEGF in hearts with acute myocardial infarction were 
measured using an ELISA assay three days following surgery.  
VEGF levels in the ligation only group averaged 15.6 ± 6.3 pg/g heart tissue, 
while levels in the untransfected myoblast group averaged 33.7 ± 8.5 pg/g heart tissue. 
The VEGF-transfected myoblast transplantation group showed a much higher level of 
VEGF expression than both the ligation only and untransfected myoblast groups 
(66.3 ± 8.1 pg/g, P < 0.001 vs. ligation only, P < 0.05 vs. myoblast only) (Figure 3.1). 
Detection of human VEGF165 in the ligation only and untransfected myoblast groups was 
most likely due to cross-reactivity between human VEGF and endogenous rat VEGF. 
3.4.2 Cardiac MRI Analysis 
Four weeks following treatment, cardiac MRI was performed on all animals. The 
thoracotomy only group had an LV ejection fraction of 67.56 ± 2.86%, which falls within 
the range of expected ejection fractions for normal rat hearts [23]. The hearts that 
underwent ligation of the LAD to induce a myocardial infarction followed by injection of 
VEGF-transfected myoblasts showed no significant decrease in LV ejection fraction 
(61.68 ± 2.83%) compared to the control, i.e., thoracotomy only, animals. Compared to 
both the thoracotomy only and VEGF165-transfected myoblast injection groups, the LV 
ejection fraction was significantly decreased in both the ligation only (48.18 ± 2.53%, 






Figure 3.1. Human VEGF expression in rat hearts three days after surgery as measured by 
ELISA. VEGF levels were significantly higher in the VEGF165-transfected myoblast 
group than the ligation and myoblast only groups (P<0.001 vs ligation; P<0.05 vs 
myoblast only). All data are presented as mean values  SEM (n=8 ligation, n=8 
myoblast only, n=8 VEGF myoblast group). 
106 
Measurement of end diastolic volume (EDV) and end systolic volume (ESV) 
revealed a similar trend, with the VEGF-transfected myoblast treatment group showing 
no significant increase in EDV or ESV compared to the thoracotomy only control group 
(EDV, 81.2 ± 3.9 µl vs. 75.55 ± 10.3 µl, respectively and ESV 24.9 ± 3.8 µl vs. 
24.2 ± 0.7 µl, respectively). The ligation only control group (EDV, 113.0 ± 4.0 µl; ESV 
42.3 ± 3.7 µl) and untransfected myoblast treatment group (EDV, 110.7 ± 6.2 µl; ESV 
42.4 ± 3.7 µl) displayed significant increases in EDV and ESV over the 4-week time 
period compared to both the thoracotomy only and VEGF-transfected myoblast treatment 
groups (P < 0.01, both groups) (Figures 3.2b, c). 
The final cardiac parameters measured from MRI were end diastolic wall 
thickness (EDWT) and end systolic wall thickness (ESWT). The thoracotomy only 
control group and VEGF-transfected myoblast treatment group showed no difference in 
wall thickness in either diastole or systole (EDWT, 2.91 ± 0.18 mm vs. 2.73 ± 0.09 mm, 
respectively; ESWT, 3.94 ± 0.13 mm vs. 3.98 ± 0.19 mm, respectively). The ligation only 
and the untransfected myoblast treatment groups displayed significant thinning of the left 
ventricular wall at both end diastole (EDWT, 2.09 ± 0.09 mm and 2.14 ± 0.10 mm, 
respectively) and end systole (ESWT, 2.91 ± 0.14 mm and 2.73 ± 0.12 mm, respectively) 
compared to the thoracotomy only (P < 0.001) and VEGF-transfected myoblast treatment 
groups (P < 0.001), (Figure 3.2d). 
3.4.3 Effect of Transfected Myoblast Transplantation on Infarct Size 
Four weeks following surgery, hearts were cut sagittally and stained with 
Masson’s trichrome. Figures 3.3b–e show representative Masson’s trichrome staining in 
rat hearts from the following groups: thoracotomy only (Figure 3.3b); ligation only (no 
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Figure 3.2. Cardiac parameters measured by MRI four weeks after treatment. (a) Cardiac 
ejection fraction. Both the VEGF myoblast and thoracotomy control groups displayed 
significantly higher ejection fractions than the ligation and myoblast only groups 
(P < 0.01). There was no significant difference in ejection fraction between the 
thoracotomy control group and the VEGF165-transfected myoblast group. (b) End 
diastolic volume (EDV). EDV significantly increased in the ligation and myoblast only 
groups compared to both thoracotomy controls and VEGF165-transfected myoblasts 
(P < 0.01). There was no significant increase in EDV between thoracotomy controls and 
the VEGF myoblast group. (c) End systolic volume (ESV). ESV significantly increased 
in the ligation and myoblast only groups compared to both thoracotomy controls and 
VEGF165-transfected myoblasts (P < 0.05). There was no significant increase in ESV 
between thoracotomy controls and the VEGF myoblast group. (d) End diastolic wall 
thickness (EDWT) four weeks post treatment. The EDWT significantly decreased in the 
ligation and myoblast only groups compared to both thoracotomy controls and VEGF165-
transfected myoblasts (P < 0.001). There was no significant decrease in EDWT between 
thoracotomy controls and the VEGF myoblast group. (e) End systolic wall thickness 
(ESWT). ESWT significantly decreased in the ligation and myoblast only groups 
compared to both thoracotomy controls and VEGF165-transfected myoblasts (P<0.001). 
There was no significant decrease in ESWT between thoracotomy controls and the VEGF 
myoblast group. All data are presented as mean ± SEM (n = 5 thoracotomy, n = 7 

































Figure 3.2. Continued. 
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injection, Figure 3.3c); injection of untransfected primary myoblasts only (Figure 3.3d); 
and injection of primary myoblasts transfected with poly(CBA-DAH)/pCMV-VEGF165 
(Figure 3.3e). On Masson’s trichrome staining, the infarct scar, characterized by high 
collagen content, is indicated by bluish staining. Ligation only, without treatment, 
resulted in infarction of 32.8 ± 7.4% of the left ventricle (Figure 3.3a). With injection of 
untransfected primary myoblasts, the infarct size decreased to 14.9 ± 1.2% of the left 
ventricle (P < 0.05 versus ligation only group). With injection of VEGF transfected 
myoblasts, the infarct size was further reduced to only 5.4 ± 3.3% of the left ventricle, 
(P < 0.001 versus the ligation only group).  
3.4.4 Enhancement of Vascular Density in Ischemic Myocardium  
Capillary endothelial cells were detected by immunostaining of the infarcted 
myocardium with antibodies to CD31. Capillaries positive for CD31 were counted in 5 
random microscope high power fields (hpf) in the ischemic border zone of each section, 
and capillary density was expressed as the average number of capillaries per field. As 
shown in representative micrographs of sections from each treatment group (Figures 3.4 
c–j), an increased number of capillaries and arterioles were present in the VEGF165-
transfected myoblast injection group than in the thoracotomy only, ligation only or 
untransfected myoblast injection groups. As shown in Figure 3.4a, immunohistochemical 
staining for smooth muscle α-actin (SMA) revealed more arterioles present in the VEGF 
transfected myoblast treatment group than any of the other groups. Mean arterioles 
positive for SMA per hpf increased from 9.2 ± 1.0 in the ligation only group to 20.4 ± 1.9 
in the VEGF transfected myoblast group (P < 0.05). Mean capillaries positive for CD31 





Figure 3.3. Masson’s trichrome staining for infarct size, four weeks after surgery. 
(a) Infarcted area as a percentage of the left ventricle. P < 0.05 for ligation only versus 
VEGF myoblast group (b–e) Representative myocardial tissue sections stained with 
Masson’s trichrome. Bluish staining indicates high collagen content, indicating 
infarction; (b) Thoracotomy only, control group, (c) ligation only, (d) untransfected 
myoblast injection group, (e) VEGF165-transfected myoblast injection group. All data are 
presented as mean ± SEM (n = 5 thoracotomy, n = 7 ligation, n = 7 myoblast only, and 
n = 7 VEGF myoblast group). 
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(P < 0.05) than in the thoracotomy only (4.1 ± 0.3), ligation only (5.2 ± 0.4) and 
untransfected myoblast (8.5 ± 0.8) groups (Figure 3.4b). 
3.4.5 Cardiomyocyte Loss in Myocardial Infarction 
Immunohistochemical staining 4 weeks after surgery was used to identify 
troponin T (cTnT) in rat heart myocardium. With troponin-T (cTnT) immunostaining, 
necrotic cardiomyocytes lose their normal brownish staining. As shown in Figure 3.5, 
cTnT in the left ventricular infarct zone was barely visible in the primary VEGF165-
transfected myoblast group (6.9 ± 0.9%), and not significantly different than the 
thoracotomy only control group (9.0 ± 1.7%). There was a significant increase in the 
number of cardiomyocytes lost in the ligation only (65.9 ± 4.8%) and untransfected 
myoblast (34.2 ± 5.1%) groups. 
3.4.6 Reduction of Apoptotic Activity in Ischemic Myocardium 
Apoptotic activity in the infarcted myocardium after treatment was measured by 
TUNEL staining. Figure 3.6 compares representative images of the TUNEL staining 
from the ischemic region in the left ventricle following thoracotomy only, ligation only, 
untransfected myoblast injection and VEGF165-transfected myoblast injection. Five 
random hpf in the ischemic border zone were selected and TUNEL-positive cells were 
counted. TUNEL-positive cells per hpf were 27.5 ± 2.3 in the ligation only group and 
21.6 ± 2.0 in the untransfected myoblast group. The number of TUNEL-positive cells in 
the infarcted zone was significantly reduced in the VEGF-transfected myoblast group 
(11.9 ± 1.4, P < 0.001 vs. ligation only). 
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Figure 3.4. Representative immunohistochemistry stains for SM α-actin and CD31 in the 
infarct border zone, 4-weeks after myocardial infarction. (c, g) Thoracotomy only, (d, h) 
ligation only, (e, i) untransfected myoblast injection and (f, j) VEGF165-transfected 
myoblast injection group. (a) Average number of smooth muscle actin (SMA)-positive 
arterioles from five random high-power fields (hpf) per animal from the ischemic border 
zone of the infarct. The number of arterioles in the VEGF165-transfected myoblast group 
was significantly greater than all other groups P < 0.001. (b) Average number of CD31-
positive capillaries from five random hpf per animal from the ischemic border zone of the 
infarct. The number of capillaries in the VEGF165-transfected myoblast group was 
significantly greater than all other groups P < 0.001. The average number of capillaries in 
the myoblast only group was significantly higher than both thoracotomy and ligation 
groups; P < 0.01 and P < 0.05, respectively. All data are presented as mean ± SEM (n = 5 












Figure 3.5. The loss of cardiomyocytes, 4-weeks after surgery as indicated by loss of 
immunohistochemical staining for cTnT; (a) Loss of cardiomyocytes from the infarct 
border zone 4-weeks after surgery identified from cTnT staining and represented as 
percent cardiomyocytes lost per hpf. Five random hpf were counted per animal. The loss 
of cardiomyocytes was significantly prevented in both the myoblast only group 
(P < 0.001 vs. ligation) and the VEGF myoblast group (P < 0.001 vs. ligation and 
myoblast only). Additionally, the ligation and myoblast only groups were statistically 
greater than the thoracotomy control (P < 0.001), whereas the VEGF myoblast treatment 
group was not statistically different from thoracotomy control. Representative 
micrographs of cTnT staining for (b) thoracotomy control group, (c) ligation, (d) 
myoblast only injection group and (e) VEGF165-transfected myoblast injection group. 
With cell death, myofibers lose their usual normal brownish staining. All data are 
presented as mean ± SEM (n = 5 thoracotomy, n = 7 ligation, n = 7 myoblast only, and 





Figure 3.6. TUNEL staining for apoptotic activity, 4-weeks after surgery. (a) TUNEL 
staining for apoptotic cells 4-weeks after surgery. TUNEL-positive apoptotic cells were 
counted in the five random hpf per animal in the ischemic border zone. The average 
number of apoptotic cells was statistically greater between thoracotomy control and all 
groups with less significance between thoracotomy and the VEGF myoblast group. 
(P < 0.001 thoracotomy vs. ligation and myoblast only; P < 0.05 between thoracotomy 
and VEGF myoblast group). The VEGF myoblast group had significantly fewer apoptotic 
cells than the ligation group (P < 0.001) and the myoblast only group (P < 0.01). There 
was no significant difference between the myoblast only treatment group and ligation 
controls. Representative micrographs of apoptotic nuclei by TUNEL staining in (b) 
thoracotomy control group, (c) ligation, (d) myoblast only injection group and (e) 
VEGF165-transfected myoblast injection group. All data are presented as mean ± SEM 




Exogenous primary myoblast transplantation into ischemic myocardium offers 
many potential benefits for the treatment of myocardial infarction, including 
improvement and restoration of cardiac function. The improvement in cardiac function is 
thought to be due to the enhancement of the contractile properties of endogenous 
cardiomyocytes and the differentiation and proliferation of implanted myoblasts into 
functional myocardium within ischemic hearts. Recent studies have demonstrated the 
feasibility of primary myoblast transplantation for the treatment of ischemic heart disease 
[18, 24]. In addition, we have previously reported that VEGF gene therapy, particularly 
ischemia-inducible VEGF gene therapy, significantly improves myocardial function and 
reduces left ventricular infarct size following acute myocardial infarction [25, 26]. 
Because ischemic heart disease is characterized by reduced blood supply to the 
myocardium, therapeutic angiogenesis using angiogenic growth factors like VEGF may 
restore blood supply by stimulating neovascularization. Excessive VEGF expression, 
however, has been associated with heart failure and death, due to vascular tumor 
formation instead of the formation of functioning vessels [27]. We have reported that the 
new poly(disulfide amine)s, poly(CBA-DAH) and poly(CBA-DAH-R), are efficient and 
nontoxic polymeric gene carriers for the transfection of primary myoblasts and that they 
mediate controlled and optimal VEGF expression. Our previous studies laid the 
foundation for this current study by demonstrating the functional benefit of this approach 
for treating acute myocardial infarction in an in vivo rat model [17]. 
In the present study, VEGF-transfected myoblasts induced angiogenesis in a 
paracrine fashion. Immunostaining for capillaries in the ischemic zone revealed that 
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neovascularization was more pronounced around the injection sites in the infarct border 
zone. This enhancement of capillary and arteriolar density in the left ventricle by VEGF-
transfected myoblasts correlated with VEGF expression levels (Figure 3.1), and resulted 
in a decrease in infarct size and preservation of ventricular function.  
Mechanisms by which implanted myoblasts may improve ischemic heart function 
include: 1) reinforcement of the ventricular wall and 2) limitation of postinfarct scar 
expansion through strengthening and enhancement of the extracellular matrix.[1, 24] In 
addition, one of the major routes of cardiomyocyte loss in myocardial infarction is via 
apoptosis and necrosis, resulting in heart failure. There are several reports which show 
that cTnT staining levels in the infarcted myocardium are highly correlated with infarct 
size and can be used as a useful biomarker to detect myocardial injury [28, 29]. As a 
result of its high cardiac specificity, cTnT immuno-staining can identify myocardial 
damage, especially necrosis [30]. As shown by our cTnT immunostaining results, the 
transplantation of skeletal primary myoblasts transfected with VEGF more efficiently 
protects against the loss of cardiomyocytes than does injection with untransfected 
myoblasts. VEGF-transfected myoblast transplantation into ischemic myocardium 
increases VEGF expression, increases the vascular density of arterioles and capillaries, 
protects endogenous cardiomyocytes from death by apoptosis and necrosis, and 
ultimately preserves cardiac function to a significantly greater degree than untransfected 
myoblast transplantation. 
Consistent with our previous in vitro study using poly-disulfide polymers and 
bPEI for the transfection of primary myoblasts, transplantation of poly(CBA-DAH)-
VEGF myoblasts demonstrated the utility of a dual therapeutic approach to maintain 
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cardiac function and inhibit left ventricular remodeling after myocardial infarction. The 
sustained VEGF release from skeletal myoblasts resulted in: 1) increased vessel density 
and 2) decreased apoptosis and cardiomyocyte loss. 
3.6 Conclusions 
 In conclusion, our study demonstrates the enhanced angiogenic efficacy of 
VEGF-transfected myoblasts using the bioreducible cationic polymer poly(CBA-DAH) 
as a transfection agent. Treatment with poly(CBA-DAH)/VEGF-transfected myoblasts 
preserved cardiac wall thickness, restored left ventricular function, induced 
neovascularization and reduced cardiac apoptosis more effectively than untransfected 
myoblasts. This work demonstrates that combining cellular implantation therapies with 
gene therapy can potentially increase the efficacy of surgical implantation of cells and 
produce better patient outcomes. Additionally, this work illustrates the in vivo safety and 
efficacy of poly(CBA-DAH) when used in combination with implanted cells. 
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SIRNA-MEDIATED KNOCKDOWN OF BNIP3 IN RAT 
 
CARDIOMYOCYTES USING AN EFFICIENT AND 
 




Nonviral polymer gene carriers are a valuable tool for achieving nucleic acid 
delivery to a variety of cell types with high efficiency and low cytotoxicity. Specifically, 
bioreducible, disulfide-containing cationic polymers have been demonstrated to mediate 
transfection in difficult-to-transfect cell types such as primary cardiomyocytes. We tested 
a variety of novel bioreducible gene carriers for their ability to deliver DNA to rat 
cardiomyocytes efficiently while displaying low cytotoxicity. We also evaluated the 
ability of these polymers to condense nucleic acids into compact nanoparticles to protect 
from degradation. A variety of siRNA sequences towards BNIP3, a novel apoptotic 
target, were screened to identify the sequence with the greatest potency in knocking down 
BNIP3 mRNA levels. Upregulation of BNIP3 has been shown to play an important role 
in predisposing cardiomyocytes to premature cell death following myocardial infarction, 
and is known to be a potent mediator of apoptosis, autophagy, and necrosis in 
cardiomyocytes. We demonstrated that in vitro knockdown of BNIP3 siRNA in rat 
primary cardiomyocytes protected the cells from hypoxic cell death, increasing cellular 
viability and function while decreasing apoptotic/necrotic cell death. This work 
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highlights both the utility of bioreducible polymers to transfect primary cardiomyocytes 
and the potential for BNIP3 inhibition to become a therapeutic strategy to limit hypoxic-
cell death in the myocardium. 
4.2 Introduction 
The potential of genetic manipulation in treating human disease has been 
hypothesized almost since the discovery of DNA as the carrier of genetic information. 
Actual attempts at gene therapy in humans have been investigated for over 40 years now 
for its potential to treat a variety of human diseases [1, 2]. Classically, gene delivery has 
been accomplished using either physical methods such as electroporation or direct naked 
polynucleotide injection, or using attenuated viruses to deliver the genetic payload. The 
physical methods, however, are limited due to their impracticality and low efficiencies [3, 
4]. The viral methods have received a great deal more attention, but problems still arise 
due to the immunogenic nature of viruses, difficulty in manufacture and quality control, 
and in the potential for insertional mutagenesis with some vectors [5]. 
Nonviral chemical methods were developed in response to these concerns and 
limitations and seek to utilize chemicals in the forms of cationic lipids and polymers to 
act as viral mimetics—protecting nucleic acids while mediating their delivery to target 
tissues [6]. Of these two methods, cationic polymer gene therapy has emerged as a 
promising candidate for clinical gene delivery. 
Cationic polymers typically contain a high degree of primary, secondary, and 
tertiary amines, which give the polymer its cationic character and allow it to form nano-
sized complexes with nucleic acids via electrostatic interaction between the positively 
charged amines and the negatively charged nucleotide phosphate backbone. Polymer 
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characteristic such as molecular weight, degree of branching, amine content, amine pKa, 
and polydispersity affect the attributes of the condensed polymer/nucleic acid 
nanoparticle (polyplex). Polyplexes are most efficient when they are approximately 
200 nm in diameter with a slight excess positive charge on the particle surface. This size 
allows for high loading capacity, while allowing for cell entry via endocytosis, while the 
positive charge encourages interaction with the predominantly negatively charged cell 
membrane. 
The incorporation of bioreducible disulfide bonds into polymer gene carriers was 
a major innovation in increasing polymer-mediated gene transfer efficiency while 
decreasing toxicity. The first cationic polymers (such as polyethyleneimine [7] and poly-
L-lysine [8]) demonstrated highly efficient gene transfer abilities, but were limited by 
their high toxicity. A major reason for the high toxicity seen with these carriers is the 
nondegradable nature of the polymers, which causes cellular accumulation and delayed 
toxicity [9, 10]. Cationic polymers with hydrolyzable linking units were some of the next 
major innovations to decrease accumulation-mediated toxicity, but the effectiveness of 
these polymers is limited by the nonspecific hydrolysis of their bonds and the resultant 
rapid polymer degradation [11]. Building polymers using disulfide-linked monomers 
introduces several improvements over other degradable bonds: disulfide bonds are very 
stable and resistant to degradation in blood and other extracellular sites; however, despite, 
their strength, they are rapidly reduced via reaction with glutathione in the reductive 
intracellular cytoplasmic environment. 
One of the most common areas for applying gene therapy is cardiovascular 
disease. Despite significant advances in preventive, pharmacological, and interventional 
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care, cardiovascular disease remains the most common cause of death in the United 
States and developed nations [12]. Within the spectrum of cardiovascular diseases, 
myocardial infarction (MI) is one of the most common and devastating forms of heart 
disease. The deadliness of the disease is highlighted by the fact that once a patient 
experiences an MI event, their chance of dying within the next 5 years is 36% if the 
patient is a man or 47% if the patient is a woman [12]. A large portion of these deaths are 
due to heart failure caused by left ventricular remodeling, set in motion by the initial MI, 
where the infarct zone continues to expand long after blood supply has been reestablished 
[13, 14]. Multiple gene therapy strategies have been attempted to limit adverse left 
ventricular remodeling, with angiogenic, procontractile, and antiapoptotic therapies being 
some of the more common approaches [15-18]. 
In this work, we first set out to identify the polymer transfection agent that 
displays the highest transfection efficiency of cardiomyocytes while also minimizing 
cellular toxicity. This polymer was then used in further study to evaluate the effect of 
siRNA-mediated knockdown of Bcl-2/adenovirus E1B nineteen-kilodalton interacting 
protein 3 (BNIP3), a proapoptotic protein upregulated specifically under hypoxia [19-21]. 
4.3 Materials and Methods 
4.3.1 Materials 
21-mer siRNA sequences were obtained from Thermo Scientific (Waltham, MA, 
USA). Target sequences were as follows: siRNA 1 [22], 5`-
UGAGAGGUAGCAGGGCAGCdTdT-3`; siRNA 2, 5`-UACCAACAGA-
GCUGAAAUAdTdT-3`; siRNA 3, 5`-AAACUCAGAUUGGAUAUGGdTdT-3`; 
siRNA 4, 5`-CAGCUUCCGUCUCUAUUUAdTdT-3`. 
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4.3.2 Primary Rat Ventricular Cardiomyocyte Isolation 
Rat primary cardiomyocytes were isolated from 2-day-old neonatal rats using a 
commercially available neonatal cardiomyocyte isolation system (Worthington 
Biochemical, Lakewood, NJ) [23]. Briefly, hearts were quickly excised from rat pups 
under isoflurane anesthesia, rinsed twice in ice-cold HBSS, and the atria removed, 
leaving only ventricular myocytes. The ventricles were minced with dissecting scissors 
and the tissue was digested overnight at 4 °C in 50 µg/ml trypsin. The following day, 
2000 µg trypsin inhibitor were added and the myocytes were warmed and digested 
further with 1,500 Units collagenase at 37 °C for 45 minutes. The tissue was then 
dissociated gently by pipetting up and down with a 5 ml pipette and strained through a 
70 µm cell strainer (BD Falcon, Franklin Lakes, NJ). The cell solution was then 
centrifuged for 5 minutes at 100× g and the cell pellet resuspended in DMEM media 
supplemented with 10% horse serum and then plated on rat tail collagen-coated cell 
culture plates at least 24 hours before use. 
4.3.3 Synthesis of ABP and Other Polymers 
The arginine-grafted bioreducible polymer (ABP) used in this study was 
synthesized as previously detailed [24], using the backbone polymer poly(CBA-DAH) 
synthesized previously in our lab [25]. Briefly, poly(CBA-DAH) was synthesized via 
Michael reaction of equimolar amounts of N-Boc-DAH and CBA in a 9:1 v/v solution of 
MeOH/H2O. The reaction was run under nitrogen at 60 °C for 5 days and protected from 
light. The polymerization was terminated by addition of 10% N-Boc-DAH and the 
reaction was maintained for an additional 2 days. The product was precipitated with 
diethyl ether and the Boc groups were removed by addition of TFA:triisobutylsilane:H2O 
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95:2.5:2.5, v/v in an ice bath for 30 minutes. The deprotected product was precipitated 2 
additional times with diethyl ether and dialyzed against ultrapure water using a dialysis 
membrane (MWCO= 1000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA, 
USA). The solution was then lyophilized to yield pure poly(CBA-DAH). 
Arginine was grafted onto poly(CBA-DAH) by addition of 4 equivalents of 
Fmoc-Arg(pbf)-OH and HBTU, and 8 equivalents of DIPEA in DMF for 2 days at room 
temperature. The product was precipitated with diethyl ether 2 times in order to remove 
unreacted starting materials then mixed with an equal volume of piperidine (30% solution 
in DMF) for 30 minutes at room temperature to remove Fmoc groups. The product was 
again precipitated 2 times with diethyl ether and a solution of 
TFA:triisopropylsilane:H2O 95:2.5:2.5, v/v was added to the precipitate at room 
temperature for 30 minutes to deprotect the pbf groups on the arginine. After one final 
diethyl ether precipitation, the final arginine-grafted bioreducible poly(disulfide amine) 
was dialyzed against ultrapure water and lyophilized to yield a sticky solid. 
The polymer poly(cystaminebisacrylamide triethylenetetramine) (CBA-TETA) 
was synthesized by following a previously published protocol developed by our lab [26]. 
The polymer polyethylenimine-grafted-polyethyleneglycol (PEI-g-PEG) was also 
synthesized as previously detailed in the literature [27]. 
4.3.4 Luciferase Transfection Efficiency Assay 
Transfection efficiency of the various polymers was evaluated using a single 
luciferase flash reporter assay. Isolated primary rat cardiomyocytes were plated into 24-
well plates at 125,000 cells/mm
2
 and incubated until they had reached approximately 
60% confluence. On the day of transfection, 0.5 µg DNA was complexed with the 
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cationic polymers in a 5% glucose, 20 mM HEPES buffer solution at a variety of weight 
ratios to identify the most efficient formulation. The polyplexes were allowed to form 
spontaneously at room temperature for 30 minutes prior to transfection. The serum-
supplemented media was removed from all wells and replaced with serum-free media. 
The polyplexes were then added directly to the wells and the plate was incubated at 37 °C 
for 4 hours. After polyplex incubation, the serum-free media was replaced again with 
supplemented media and the cells incubated at 37 °C for 48 hours. The cells were washed 
with room temperature PBS, treated with 200 µl lysis buffer, and exposed to 2 
freeze/thaw cycles to complete the lysis. The well contents were transferred to 
microcentrifuge tubes and the cellular debris was cleared by centrifugation at 14,000× g 
for 5 minutes. To measure total protein concentration, 10 µl of the supernatant was 
transferred to a clear 96-well plate and quantified using a BCA protein assay kit (Pierce, 
Rockford, IL) with bovine serum albumin as a standard. An additional 25 µl aliquot was 
transferred to a white 96-well plate to measure luminescence. A Perkin Elmer Victor 
plate reader (Perkin Elmer, Waltham, MA) was used to automatically dispense 100 µl of 
luciferase assay buffer containing luciferin (Pierce, Rockford, IL) to the wells and 
measure the relative luminescence units (RLUs) for each well. The RLU data were then 
normalized as RLU/mg total protein. All transfection assays were performed with 
triplicate replicates and repeated three times. 
4.3.5 MTT Viability Assay 
Cellular viability was analyzed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. MTT is reduced in living cells to form an 
insoluble purple formazan crystal and is an indicator of cellular viability. Primary rat 
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cardiomyocytes were plated into 24-well plates at 125,000 cells/mm
2
 and incubated at 
37 °C until they had reached 80% confluence. DNA was complexed with the cationic 
polymers at predetermined w/w ratios in a 5% glucose, 20 mM HEPES buffer solution 
and allowed to form nanoparticles at room temperature for 30 minutes. The supplemented 
media was removed and replaced with serum free media and the polyplexes were added 
to each well. The polyplexes were incubated with the cells for 4 hours at 37 °C, after 
which the media was removed and replaced with serum supplemented media. The cells 
were returned to the incubator for approximately 16 hours. An MTT solution (50 µl of 
2 mg/ml MTT) was added to each well and the cells were returned for a further 4 hours of 
incubation. After formation of purple crystals at the bottom of the well was evident, the 
media was carefully aspirated and 300 µl of DMSO was added to each well to solubilize 
the formazan crystals. Absorbance was read at 570 nm on a microplate reader (Bio-Rad, 
Hercules, CA). Percent relative viability was determined using untreated cells as a 100% 
control level. All samples were performed in triplicate and each experiment was repeated 
a minimum of three times. 
4.3.6 Gel Retardation 
A 0.8% agarose gel containing SYBR green was prepared using tris-acetate-
EDTA (TAE) buffer. ABP:siRNA complexes were prepared with 500 ng of siRNA at 
various w/w ratios in a 5% glucose, 20 mM HEPES buffer solution and allowed to form 
polyplexes for 30 minutes at room temperature. A loading dye was added to each sample 
and the polyplexes were loaded into the wells of the prepared gel. The gel was 
electrophoresed at 110 V for 15 minutes and the RNA bands were then visualized with 
UV light on a Bio-Rad Gel Doc system (Bio-Rad, Hercules, CA). Polyplex reduction was 
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achieved by incubating siRNA polyplexes with 5 mM dithiothreitol (DTT) at 37 °C for 
30 minutes. The reduced samples were then run as described above. 
4.3.7 In Vitro Knockdown 
To perform the siRNA knockdown studies, rat primary caridomyocytes were 
seeded onto 6-well plates at 125,000 cells/cm
2
 and allowed to grow to 75% confluence. 
The cells were then treated with 50 nM siRNA complexed with ABP at a 1:20 w/w ratio 
in serum free media for 4 hours. The media was then replaced with supplemented media 
and the cells were incubated a further 48 hours. The cells were then lysed and the mRNA 
isolated using a PureLink total RNA extraction kit (Life Technologies, Carlsbad, CA). 
qRT-PCR was performed using the TaqMan One-Step RT-PCR kit (Life 
Technologies, Carlsbad, CA). Primers were acquired for rat BNIP3 (part number 
Rn00821447), and compared against the housekeeping gene L32 (part number 
Rn00820748). All probe/primer combinations were designed, validated, and purchased 
from Applied Biosciences/Life Technologies (Life Technologies, Carlsbad, CA). 
4.3.8 BNIP3 Protein ELISA 
Rat primary cardiomyocytes were seeded onto 35 mm plates at 125,000 cells/cm
2
 
and allowed to grow to 75% confluence. As above, the cells were then treated with 
50 nM siRNA complexed with ABP at a 1:20 w/w ratio in serum free media for 4 hours. 
The media was then replaced with supplemented media and the cells were incubated for 
an additional 2, 3, 5, and 7 days. The cells were then lysed and the protein isolated using 
standard microbiology techniques described briefly below. 
Whole cell lysates were prepared by aspirating the cell media, and adding 
complete RIPA lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 
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1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 
1 mM ß-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin). After a single freeze-thaw 
cycle, the cells were scraped and pipetted to ensure complete lysis. The lysates were 
transferred to a microcentrifuge tube and centrifuged for 5 minutes at 14,000× g to 
separate the debris. The supernatant was then analyzed using a 96-well plate ELISA 
specific for rat BNIP3 (Kamiya Biomedical, Seattle, WA). 
4.3.9 Contracting Cardiomyocytes 
To analyze cardiomyocyte contractile function after hypoxia exposure, rat 
primary cardiomyocytes were seeded into 35 mm plates at 125,000 cells/cm
2
 and allowed 
to grow until intercellular junctions could form and the plate of cells were beating 
synchronously (approximately 80% confluence). The cells were then treated with 50 nM 
luciferase or BNIP3 siRNA complexed with ABP at a 1:20 w/w ratio in serum free media 
for 4 hours. The media was then replaced with reduced serum media and the cells were 
incubated under hypoxic conditions (1% O2, 5% CO2, 94% N2) for 24 hours. Immediately 
after 24 hours exposure to hypoxia, the cells were removed from the incubator and 
imaged on an EVOS fluorescent microscope (AMG, Bothell, WA) using the transmitted 
light setting at 20× magnification. The total number of cardiomyocytes in each high 
power field still showing contractile activity was then counted. All results were 
normalized against the number of cells beating in the untreated hypoxic control group. 
4.3.10 In Vitro Live/Dead Assay 
Primary rat cardiomyocytes isolated as above were seeded onto 35 mm plates at a 
density of 125,000 cells/cm
2
 and allowed to grow to 75% confluence. Cells were then 
treated with 50 nM siRNA with ABP (1:20 w/w) in serum free media for 4 hours. The 
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media was then replaced with reduced serum media and the cells were incubated under 
hypoxic conditions (1% O2, 5% CO2, 94% N2) for 48 hours. The cells were then treated 
with ethidium homodimer-1 and calcein AM dyes from Invitrogen’s mammalian 
LIVE/DEAD Viability/Cytotoxicity Kit (Life Technologies, Carlsbad, CA, USA) and 
analyzed on an EVOS fl fluorescent microscope (AMG, Bothell, WA, USA). The number 
of positive cells in both the live and dead channels was counted from a total of 3 random 
fields from each sample. Data were reported as fold normoxia control levels. 
To perform the in vitro live/dead assay, primary rat neonatal cardiomyocytes were 
seeded onto 35 mm cell culture plates coated with a collagen-based attachment factor at 
approximately 150,000 cells/cm
2
. Once the cells had reached 60–75% confluence, the 
FBS-supplemented media was replaced with serum free medium and the cells were 
treated with 50 nM of BNIP3 siRNA complexed at 1:20 w/w with ABP, 50 nM luciferase 
siRNA complexed at 1:20 w/w with ABP, or no siRNA at all. The serum free media was 
replaced with FBS-supplemented media after 4 hours and the cells were incubated for 
24 hours under normal cell culture conditions. After 24 hours, the cells were transferred 
to a hypoxia chamber containing 1% O2, 5% CO2, 94% N2 and incubated in reduced 
serum (1% FBS) for an additional 24 hours.  
After incubation under hypoxia, the plates were removed from the incubator and 
rinsed three times with Dubelcco’s phosphate-buffered saline to reduce extracellular 
esterase activity. They were then immediately treated with 2 µM calcein AM and 4 µM 
ethidium homodimer-1. The cells were then incubated in the dark for 45 minutes at room 
temperature. After incubation, the cells were viewed on an EVOS fluorescent microscope 
(AMG, Bothell, WA) using a 470/22 nm excitation with 525/50 nm emission window for 
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calcein AM, and a 531/40 nm excitation with 593/40 nm emission window for ethidium 
homodimer-1. 
4.3.11 Statistical Analysis 
All results are reported as the mean value ± standard error of the mean (SEM). 
Statistical analysis was performed in GraphPad Prism 4.03 (GraphPad Software, La Jolla, 
CA, USA) using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc 
test to identify significance between groups. P < 0.05 was considered statistically 
significant throughout. 
4.4 Results 
The polymer ABP was synthesized according to the reaction scheme in 
Figure 4.1. The structure was confirmed by NMR, mass-spectrometry, and FTIR (data 
not shown). The structures of the other polymers evaluated for transfection efficiency and 
cytotoxicity are included in Figure 4.2. The structure of CBA-TETA was unique from the 
other bioreducible compounds evaluated as it forms a branched cationic polymer as 
opposed to a linear polymer, as shown in Figure 4.1.  
4.4.1 Transfection Efficiency 
Luciferase expression is commonly used to evaluate transfection efficiency as it 
indicates the efficiency of cellular entry, endosomal escape, polymer dissociation from its 
nucleic acid cargo, nuclear penetration, and ultimately, transcription and translation of the 
plasmid DNA. We evaluated a large number of polymers at varying polymer:DNA 
weight ratios to identify not only the most efficient polymer but also to determine the 














Figure 4.2. Chemical structures of cationic polymers screened to transfect rat 
cardiomyocytes. TETA = triethylenetetramine, ABP = arginine-grafted bioreducible 
polymer, DAH = diaminohexane, PEI-g-PEG = polyethyleneimine-grafted 
polyethyleneglycol. 
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higher transfection efficiency than bPEI at all weight ratios and demonstrated 
significantly higher transfection efficiency than all other polymer formulations, with the 
exception of TETA at 10:1 (Figure 4.3). Notably, most other polymers did not perform as 
well as the bPEI benchmark whereas ABP showed 2.9-fold higher expression at 20:1, 
8.9-fold higher expression at 40:1, and 30.0-fold higher expression at 60:1. The steadily 
increasing transfection efficiencies as weight ratio increases is typical for polyplex 
delivery systems; however, as the weight ratio increases, so does toxicity. 
4.4.2 MTT Viability Assay 
Evaluating the cytotoxic effects of polyplex gene delivery is of obvious 
importance as high transgene expression is of limited value if most of the cells are killed 
by the treatment. Using the MTT viability assay, we evaluated the toxicity of the 
experimental conditions tested for luciferase expression. As expected, the toxicity of the 
polyplexes becomes more pronounced as the polymer:DNA weight ratio increases. Even 
though TETA at 10:1 showed improved transfection efficiency compared to bPEI, the 
treatment condition killed 10% of the cells, limiting its effectiveness (Figure 4.4). 
However, ABP at 20:1 showed no toxicity towards cardiomyocytes compared to 
untreated control cells. As the weight ratio of ABP:DNA increases, significant toxicity 
becomes apparent. While the 40:1 and 60:1 formulations of ABP showed progressively 
increasing transfection efficiencies, the accompanying increase in toxicity negated the 
benefit. A degree of toxicity is acceptable for in vitro experimentation as the transfected 
cells can replicate to replace the cells lost due to polyplex toxicity or a larger number of 





Figure 4.3. Luciferase transfection efficiency assay of various cationic polymers on rat 
cardiomyocytes. The dashed line indicates the expression level achieved by transfection 
of luciferase with 25 kDa bPEI. 
  























Figure 4.4. MTT viability assay of various cationic polymers on rat cardiomyocytes. All 
results reported as a percentage of untransfected control cells. The dashed line indicates 
100% viability as determined by untransfected controls. 


























vivo animal model, even small levels of toxicity are unacceptable. This is especially true 
in the heart, which is known for very low cellular turnover and a limited capacity for self-
renewal. For these reasons, all subsequent studies were performed with ABP at a weight 
ratio of 20:1. 
4.4.3 Gel Retardation 
Gel retardation assays, also known as gel electrophoresis mobility shift assays, 
reveal the capacity of the polyplex to bind and complex DNA tightly and efficiently. If 
the polyplex formulation condenses DNA or siRNA, it prevents it from migrating 
through the gel and no band is visible. The gel retardation study was performed on the 
selected ABP polymer at weight ratios of 0.5:1, 1:1, 5:1, 10:1, 20:1, and 40:1 
ABP:siRNA to ensure that the polymer forms tight complexes to provide for protection 
from degradation by nucleases. ABP demonstrated that it can condense siRNA at weight 
ratios 20:1 and 40:1, as evidenced by the significantly lighter bands (Figure 4.5, top). 
The addition of the chemical agent DTT reduced the disulfide bonds in the 
polymer, freeing the siRNA and allowing all bands to migrate (Figure 4.5, bottom). Even 
the higher 20:1, and 40:1 w/w ratio polyplexes were completely degraded, demonstrating 
the ability of the polymers to break down and dissociate from nucleic acids under 
reducing conditions similar to that experienced in the cytoplasm. 
4.4.4 BNIP3 Sequence Selection 
In order to identify the most potent siRNA for use in our future studies, we 
compared a previously published sequence of siRNA (siRNA 1, sense strand 5’-
GCUGCCCUGCUACCUCUCAdTdT-3’) [22] with three sequences designed using 





Figure 4.5. Gel retardation assay of ABP:siRNA polyplexes at 0.5:1, 1:1, 5:1, 10:1, 20:1, 
and 40:1 w/w ratios. The top panel is without the addition of the reducing agent DTT, 
while the bottom panel contains 5 mM DTT to reduce disulfide bonds.  
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Table 4.1. siRNA Sequences Tested for BNIP3 Knockdown Potency 
 
 
Sequence Name Target Sequence (5`-3`) 
siBNIP3 1 UGAGAGGUAGCAGGGCAGCdTdT 
siBNIP3 2 UACCAACAGAGCUGAAAUAdTdT 
siBNIP3 3 AAACUCAGAUUGGAUAUGGdTdT 
siBNIP3 4 CAGCUUCCGUCUCUAUUUAdTdT 
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We compared the knockdown of BNIP3 mRNA in rat primary cardiomyocytes treated 
with 50 nM siRNA complexed with ABP at 1:20 w/w ratio. After 48 hours, total RNA 
was isolated and analyzed for relative BNIP3 levels compared to untreated controls and 
normalized against the ribosomal protein L32 by qRT-PCR.  The qRT-PCR results 
indicated that the previously published siRNA (siRNA 1) was the most potent, decreasing 
BNIP3 mRNA levels to an average of 36.8 ± 8.1% of normal versus an average of 
59.0 ± 16.6%, 54.7 ± 6.3%, and 62.7 ± 3.4% for the alternative sequences (Figure 4.6). 
4.4.5 BNIP3 Protein Knockdown Confirmation 
In order to ensure the sequence selected above by qRT-PCR also produced 
knockdown of BNIP3 protein, an ELISA was used to evaluate relative protein levels. 
BNIP3 protein levels were immediately reduced from baseline levels as soon as 24 hours 
after transfection with BNIP3 siRNA (Figure 4.7). Protein levels were reduced 30% from 
normal and were maintained at this decreased level through day 5 (P < 0.01). At day 7, 
BNIP3 levels increased and while they remained reduced from control levels, they were 
no longer significantly lower. 
4.4.6 Hypoxia Protection and Functional Cardiomyocytes 
The fractional survival of cells exposed to hypoxia is not the only predictor of 
function after myocardial infarction. It is also important that cells are able to maintain 
function after exposure to harsh conditions that would be experienced in an infarcted 
region. Inhibition of BNIP3 using siRNA in rat primary cardiomyocytes significantly 
improved contractile function after exposure to severe hypoxic conditions for 24 hours. 





Figure 4.6. qRT-PCR knockdown of rat BNIP3 in rat primary cardiomyocytes. The graph 
shows that the previously published BNIP3 siRNA sequence was the most potent siRNA 




























































Figure 4.7. siRNA knockdown of BNIP3 protein over a 7-day period. All time points are 
normalized against nontransfected controls. 

























function compared to both untreated controls and siLuc-treated cardiomyocytes 
(P < 0.001)(Figure 4.8). 
4.4.7 In Vitro Viability Live/Dead Assay 
In order to initially validate the ability of BNIP3 inhibition to protect 
cardiomyocytes from apoptosis and retain cell viability, we performed a live/dead assay 
on primary rat ventricular cardiomyocytes under hypoxic conditions for 24 hours. 
Compared to normoxic controls, cells transfected with siBNIP3:ABP at a 1:20 w/w ratio 
remained viable (97% of normoxic, P < 0.001 vs. hypoxic controls). Significant loss of 
viability was observed in both untreated hypoxic cells (40% of normoxic) and in 
nontargeting siLuc:ABP-treated cells (50% of normoxic) (Figure 4.9a). 
The same pattern of hypoxia protection was evident when evaluating dead/dying 
cells with condensed nuclei and disrupted cell membranes. The siBNIP3:ABP-transfected 
cells were not significantly increased over normoxic levels. The level of dead cells was 
less than 50% of that seen in untreated hypoxic controls and in nontargeted siLuc-
transfected cells (P < 0.001)(Figure 4.9b). 
4.5 Discussion 
The primary barrier limiting the clinical potential of gene therapy remains the lack 
of nontoxic, nonimmunogenic, gene delivery agents that produce high transgene 
expression or mediate efficient mRNA knockdown by RNAi. Here we show that 
bioreducible cationic polymers can transfect rat primary cardiomyocytes, producing high 
expression of plasmid DNA, and efficient knockdown mediated by siRNA. We also 
demonstrate that we are able to attain these high gene delivery levels without causing 





Figure 4.8. Beating cardiomyocytes after siRNA-mediated knockdown of BNIP3 and 


































































































































































While polymeric gene delivery had been observed before, the true potential for 
polymers to act as efficient gene delivery agents was not fully appreciated until 
Behr et al. reported the versatility of polyethyleneimine (PEI) for oligonucleotide transfer 
[7]. Since that time, PEI has become the gold standard for polymer transfection, but its 
usefulness is limited by its high charge density and nondegradable nature [28]. 
Bioreducible polymers still mediate high transfection efficiency and condense nucleic 
acids to nano-sized particles, but their disulfide bonds rapidly degrade upon entry to the 
cytosol, allowing for rapid polyplex unpackaging and clearance of the smaller molecular 
weight polymer fragments. 
We demonstrated that of the bioreducible and nondegradable polymers 
investigated, ABP was both highly efficient and nontoxic to cardiomyocytes. Our lab has 
previously shown that ABP can transfect a wide number of cell types with low toxicity 
and high efficiency [24, 29]. However, the ability of ABP to transfect primary cells, 
especially cardiomyocytes, had not been investigated. In addition to the positive 
luciferase results demonstrating that ABP was the most efficient gene delivery agent for 
cardiomyocytes, we also determined that ABP was essentially nontoxic to 
cardiomyocytes at a 20:1 weight ratio. While higher transfection efficiency was observed 
at 40:1 and 60:1 weight ratios, the toxicity associated with those formulations precludes 
them from use in an in vivo setting, where cell loss incidental to transfection is not 
acceptable. 
The proapoptotic protein BNIP3 has long been known to play an important role in 
causing cell death in a number of tissue types such as neurons [30, 31] and 
cardiomyocytes [21, 32-34]. Additionally, BNIP3 loss-of-function mutations and 
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decreased expression are common in many hypoxia-resistant, metastatic cancers [35, 36] 
and are indicators of poor prognosis [37]. Previous studies have demonstrated that BNIP3 
deletion or interference has a protective effect on hypoxic cardiomyocytes [34, 38-42]; 
however, no one has demonstrated the protective effect of siRNA knockdown of BNIP3 
on hypoxia survival. Here we show that BNIP3 interference via siRNA produces rapid 
and significant decreases in both BNIP3 mRNA and more importantly, protein levels. 
This rapid and significant decrease makes siRNA knockdown of BNIP3 a viable 
therapeutic strategy to prevent cell death due to MI possible as cell death due to ischemia 
is known to peak within the first few days after MI [43, 44]. While the levels of BNIP3 
protein knockdown were not as significant as those observed at an mRNA level, BNIP3 
is not highly expressed in normoxic cells, and in situations of elevated BNIP3 expression 
such as hypoxia, the knockdown of BNIP3 protein may be more significant. 
Finally, we also demonstrated that the immediate decrease in BNIP3 mRNA and 
protein levels produced a protective response to harsh hypoxic conditions. Interference 
with BNIP3 transcription and translation increased the number of viable cells after 
hypoxia, decreased the number of necrotic/apoptotic cells, and also increased the 
contractile performance of cells after prolonged hypoxia exposure. 
4.6 Conclusions 
In conclusion, this work has established that nonviral bioreducible polymers can 
act as gene delivery agents to secondary and primary rat cardiomyocytes with high 
efficiency of gene expression/siRNA-mediated mRNA knockdown, and low toxicity. 
Furthermore, we demonstrated that the proapoptotic protein BNIP3 is a valid target for 
the prevention of cell death due to exposure to harsh hypoxia conditions, as BNIP3 
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mRNA inhibition resulted in increased cardiomyocyte function and viability versus 
untreated or nontargeting siRNA controls. Therefore, BNIP3 knockdown via RNAi is a 
viable option to reduce cardiomyocyte death due to hypoxic injury and should be 
investigated in animal models of myocardial infarction. 
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Apoptosis in the myocardium following myocardial infarction is purported to be a 
major contributing factor to infarct expansion and negative remodeling of the left 
ventricle. In human patients and in animal models of myocardial ischemia/reperfusion 
(I/R) injury, the hypoxia-responsive, proapoptotic protein BNIP3 is consistently 
upregulated in the myocardial infarct zone, suggesting an important role in cardiac 
apoptosis. In this work, we hypothesized that polymer-mediated siRNA gene therapy to 
knockdown BNIP3 would reduce apoptosis in a rat model of I/R and lead to retained 
heart function and decreased left ventricle remodeling. After a temporary 30-minute 
ligation of the left anterior descending coronary artery, rats were randomly divided 
between five groups: 1) BNIP3 siRNA complexed with a novel cationic, disulfide-linked 
arginine-grafted bioreducible polymer (ABP), siBNIP3:ABP, 2) nontargeting luciferase 
siRNA complexed with ABP, siLuc:ABP, 3) naked siBNIP3, 4) I/R but no treatment, and 
5) thoracotomy sham surgery control. After 2 weeks of treatment, siBNIP3:ABP-treated 
rats demonstrated elevated ejection fraction versus I/R controls (74.4 ± 4.4% vs. 
58.4 ± 3.9%). Improvements in regional wall thickening and end systolic volume versus 
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untreated controls were also observed. Infarcts in siBNIP3:ABP rats were over 50% 
smaller than in I/R only, nontargeting siLuc:ABP, and naked BNIP3 control groups. 
Significant decreases in TUNEL-positive cells were also observed in the siBNIP3:ABP 
treatment group. Our results demonstrate the potential utility of an RNAi treatment 
paradigm to reduce cell death after myocardial infarction and improve heart function by 
targeting BNIP3. 
5.2 Introduction 
While rates of cardiovascular disease have been in decline over the years, it 
remains the top cause of death among developed countries. In the United States alone, it 
accounts for one out of three deaths, totaling 811,900 deaths in 2008 [1]. Myocardial 
infarction (MI) is a form of coronary heart disease caused by decreased blood flow and, 
concomitantly, oxygen supply to the myocardium, causing ischemic cell death. This 
reduction in blood flow is most commonly caused by a plaque or thrombotic occlusion in 
one of the coronary arteries. In the event of an MI, the most common medical response is 
to attempt to reestablish blood flow to the heart through the use of pharmacological 
agents which clear thrombi within the coronary arteries or via primary percutaneous 
coronary intervention. Research has revealed, however, that the rapid reestablishment of 
oxygen supply to the hypoxic myocardium results in a reperfusion injury caused by the 
rapid increase in reactive oxygen to tissues that have begun to compensate for the 
lowered oxygen state, thereby increasing their susceptibility to oxidative damage [2-5]. 
This complex series of events creates a multifaceted pathology that must be considered 
when attempting to develop new therapies to improve the treatment of MI. 
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Of principle importance to the treatment of infarcted myocardium is the 
prevention of left ventricular remodeling that occurs after MI [6]. The infarct zone is not 
static and even after blood flow has been restored and the vasculature has been repaired, 
the infarct continues to slowly expand to encompass an ever larger portion of the 
ventricle [7]. Infarct expansion and left ventricular remodeling occur due to complex 
interplay of neurohormonal, mechanical, and biochemical compensatory factors that end 
in maladaptive remodeling of the left ventricle, leading to heart failure [8]. 
Gene therapy has been investigated in both research and clinical settings as a 
potential treatment for myocardial infarction [9]. Most gene therapy studies, especially 
those with clinical data, however, have focused on proangiogenic approaches to 
revascularize the myocardium and promote tissue survival [10-12]. Another important 
therapeutic strategy for myocardial gene therapy of ischemic heart disease, however, is 
the prevention of cell death via apoptosis, necrosis, and autophagy to preserve 
endogenous cardiomyocytes [13-15]. Several research studies have evaluated viral and 
nonviral DNA therapy to express proteins that protect against apoptosis such as Bcl-2 
[16] and TNF-α receptor 1 [17]. Other groups have evaluated siRNA treatment to lower 
levels of genes that directly or indirectly contribute to apoptosis such as SHP-1 [18], 
ALOX5 [19], PTP-1B [20], and PHD2 [21, 22]. 
Bcl-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) is a proapoptotic 
member of the Bcl-2 apoptosis family. The BNIP3 protein is unique, however, as it is the 
only proapoptotic protein with a hypoxia response element (HRE) upstream [23]. This 
HRE is activated by the oxygen-sensitive Hif-1 transcription factor complex, 
upregulating expression of downstream genes during periods of hypoxic stress. Most 
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genes with HREs are prorecovery factors like GLUT-1 [24], VEGF [25], and 
erythropoietin [26], but BNIP3 appears to be the only HRE-containing gene with direct 
proapoptotic activity [27]. Importantly, BNIP3 has been shown to play an important role 
in MI [28]. In mouse models of MI, BNIP3-overexpression decreased LV function, 
increased apoptosis, and increased LV dilation whereas BNIP3-knockout mice showed 
lower levels of apoptosis, improved LV function, and lower levels of LV dilation [29].  
The aim of this study was to utilize an efficient and nontoxic bioreducible 
polymer delivery system to locally deliver BNIP3 siRNA to the infarcted rat heart in 
vivo. We have previously established the high transfection efficiency and low toxicity of 
our arginine-grafted bioreducible polymer (ABP) in a variety of cell types, including 
myoblasts [30, 31]. We used this novel cell-penetrating polymer to deliver BNIP3 siRNA 
and investigate the hypothesis that transient reduction of BNIP3 levels in the infarcted 
heart leads to increased cardiomyocyte protection, decreased left ventricular remodeling, 
and retention of heart function. 
5.3 Materials and Methods 
All experiments were approved by the University of Utah’s Institutional Animal 
Care and Use Committee and followed the guidelines provided by the National Institutes 
of Health in Guide for the Care and Use of Laboratory Animals. 
5.3.1 Materials 
BNIP3 siRNA was obtained from Thermo Scientific (Waltham, MA, USA). The 
target strand sequence was as follows: 5`-UGAGAGGUAGCAGGGCAGCdTdT-3`. 
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5.3.2 Synthesis of ABP Polymer 
The arginine-grafted bioreducible polymer (ABP) used in this study was 
synthesized as previously detailed [30], using the backbone polymer poly(CBA-DAH) 
synthesized previously in our lab [32]. Briefly, poly(CBA-DAH) was synthesized via 
Michael reaction of equimolar amounts of N-Boc-DAH and CBA in a 9:1 v/v solution of 
MeOH/H2O. The reaction was run under nitrogen at 60 °C for 5 days and protected from 
light. The polymerization was terminated by addition of 10% N-Boc-DAH and the 
reaction was maintained for an additional 2 days. The product was precipitated with 
diethyl ether and the Boc groups were removed by addition of TFA:triisobutylsilane:H2O, 
95:2.5:2.5 (v/v) in an ice bath for 30 minutes. The deprotected product was precipitated 2 
additional times with diethyl ether and dialyzed against ultrapure water using a dialysis 
membrane (MWCO= 1000 Da, Spectrum Laboratories, Inc., Rancho Dominguez, CA, 
USA). The solution was then lyophilized to yield pure poly(CBA-DAH). 
Arginine was grafted onto poly(CBA-DAH) by addition of 4 equivalents of 
Fmoc-Arg(pbf)-OH and HBTU, and 8 equivalents of DIPEA in DMF for 2 days at room 
temperature. The product was precipitated with diethyl ether 2 times in order to remove 
unreacted starting materials then mixed with an equal volume of piperidine (30% solution 
in DMF) for 30 minutes at room temperature to remove Fmoc groups. The product was 
again precipitated 2 times with diethyl ether and a solution of 
TFA:triisopropylsilane:H2O, 95:2.5:2.5 (v/v) was added to the precipitate at room 
temperature for 30 minutes to deprotect the pbf groups on the arginine. After one final 
diethyl ether precipitation, the final arginine-grafted bioreducible poly(disulfide amine) 
was dialyzed against ultrapure water and lyophilized to yield a sticky solid. 
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5.3.3 Vertebrate Animals 
All animal experiments were performed according to protocols approved by the 
University of Utah’s Institutional Animal Care and Use Committee. Sprague Dawley rats 
were purchased from Charles River Laboratories International, Inc. (Wilmington, MA, 
USA). The rats were housed under the care of a licensed veterinarian and monitored daily 
for signs of sickness or pain after surgery. The animals had free access to normal rat 
chow and water and were kept with a 12-hour light-dark schedule. 
5.3.4 Rat Ischemia/Reperfusion Model 
Male Sprague Dawley rats (approximately 300 g) were anesthetized under 4% 
isoflurane, given an intramuscular injection of ketamine, and had their left chests shaved. 
After allowing 10 minutes for the ketamine to take effect, the rats were again 
anesthetized with 4% isoflurane and intubated by hanging the rats from their incisors and 
inserting a 12 G IV catheter over a 0.035” guidewire past the vocal cords into the trachea. 
The rat was quickly moved to a water-warmed operating table and connected to a 
ventilator delivering 2% isoflurane at 60 cycles/minute with a 12 ml/kg stroke volume. 




 rib and the ribs spread using a retractor to 
gain access to the chest cavity. The left lung was swept dorsally to visualize the heart and 
held out of the way using a wet 2” × 2” gauze pad. The pericardium was carefully 
removed and the left anterior descending artery (LAD) identified. A 6-0 prolene suture 
was passed under the LAD approximately 2 mm from the edge of the left atrial 
appendage and the needle cut from the suture. The two ends of the suture were then 
threaded through a 2 cm length of PE-50 tubing (Becton Dickinson, Franklin Lakes, NJ, 
USA) to form a snare. The two ends of the suture were pulled tight and the tubing was 
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clamped with a pair of needle drivers to occlude the LAD. After confirming successful 
occlusion of the LAD by blanching of the myocardium and visible dyskinesia of the LV 
wall the animals were assigned to one of 5 groups: 1) ischemia/reperfusion (I/R) only 
(n = 7), 2) nontargeting siLuc:ABP (n = 5), 3) naked siBNIP3 (n = 5), 4) siBNIP3/ABP 
(n = 7), and 5) thoracotomy sham surgery control (n = 5). After 30 minutes, the snare was 
loosened, the suture removed from the myocardium, and an injection of 25 µg siRNA 
complexed with 500 µg ABP (1:20 w/w) for the siRNA groups or 25 µg naked siRNA in 
100 µl 1X PBS were injected intramyocardially in 4 sites (3 sites around the ischemic 
border zone, 1 site in the central infarct zone). The chest was then closed in layers using 
resorbable sutures and the rats were allowed to recover under a warming lamp and given 
injections of pain alleviating medication (buprenorphine) and antibiotics (cefazolin). The 
sham surgery control animals received a thoracotomy and had a suture passed under the 
LAD without tightening before closing the surgical site. 
5.3.5 Magnetic Resonance Imaging 
Three weeks after surgery, MRI was performed to determine changes in indices of 
heart function in all animals. Cardiac Cine-MRI was used to measure parameters of heart 
function and anatomy. MRI scans were performed on isoflurane-anesthetized rats placed 
prone on a pressure sensor to monitor respiration and a pulse oximeter attached to the 
rat’s foot. A Bruker Biospec 7T/30 cm MRI operated with Bruker AVANCE II 
electronics (Bruker BioSpin MRI GmbH, Ettlingen, Germany) with a Bruker birdcage 
quadrature resonator (72 mm internal diameter) was used for signal transmission and 
reception. The images were acquired using retrospectively gated fast-low-shot-angle 
(FLASH) pulse sequences in CINE mode. The instrument settings were as follows: 
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repetition time (TR) = 72 ms, echo time (TE) = 3 ms, flip-angle = 10°, number of 
repetitions = 100, field of view (FOV) = 40 mm × 55 mm, matrix size = 196 × 96 zero-
padded to 392 × 192 yielding an effective in-plane resolution of 102 × 286 microns. A 
total of 7 short-axis scans (slice thickness = 1.5 mm, number of movie frames = 10) were 
acquired. Images were reconstructed using Bruker’s Intragate software and exported as 
DICOM files for analysis. The resulting Cine-MRI images were used to analyze left 
ventricle ejection fraction, end-diastolic and end-systolic wall thickness, and end-
diastolic and end-systolic volume using the freely available software Segment v1.8 
(Segment; http://segment.heiberg.se) [33]. Papillary muscles were included for all 
volume and ejection fraction measurements, but were excluded to perform analysis of the 
ventricle wall. An investigator blinded to the treatment groups analyzed the left ventricle 
in a semi-automated manner and another blinded investigator reviewed the results for 
accuracy and quality control. 
5.3.6 Histology and Immunochemistry 
The day following MRI acquisition, the rats were sacrificed by overdose of 
isoflurane. The hearts were rapidly excised and washed/perfused 3 times each with 20 ml 
heparin-PBS, 20 ml 2.56 M KCl, and 10% formalin. The hearts were then fixed in 10% 
formalin at room temperature for 48 hours, after which they were transferred to and 
stored in 70% EtOH until sectioning. Hearts were sectioned along the short axis from 
base to apex by slicing every 2 mm using an acrylic tissue matrix and embedded in 
paraffin (Zivic Instruments, Pittsburg, PA, USA). The paraffin-embedded short axis 
slices were then air dried for at least 30 minutes at room temperature and placed in a dry 
55–60 °C oven for an additional 30 minutes. The slides were then de-paraffinized in 3 
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changes of xylene (5 minutes each), rehydrated in ethanol (100% ×2, 95% ×2, 70% ×1, 
1 minute each), and finally placed in dH2O. All histology and immunohistochemical 
staining steps were performed at 37 °C with an automated immunostainer (BenchMark® 
XT, Ventana Medical Systems, Tucson, AZ, USA). 
Heart sections were stained using Masson’s trichrome to quantitatively analyze 
the extent of infarct formation. Trichrome-stained heart slides were scanned for analysis 
using a standard desktop scanner at 600 dpi (CanoScan 8800F, Canon USA, Inc., Lake 
Success, NY, USA). The infarct size within the left ventricle was calculated by outlining 
the collagen-stained area, the total left ventricle epicardial area, and the total left ventricle 
endocardial area in ImageJ (NIH, Bethesda, MA, USA). Percent infarct was calculated 
using the following equation. 
 
Additional heart sections were stained using a rabbit anti-rat BNIP3 antibody 
(Abcam, Cambridge, MA, USA). Sections were incubated at room temperature with the 
primary BNIP3 antibody at a 1:300 dilution for 20 minutes. The secondary antibody was 
applied at 1:100 for 20 minutes. The sections were detected using the indirect biotin 
streptavidin system iVIEW DAB that uses the chromogen DAB (3-3’ diaminobenzidine) 
(Ventana Medical Systems, Tucson, AZ, USA). Slides were counterstained with 
hematoxylin and dehydrated by reversing the ethanol sequence above. 
Apoptotic cells were detected by staining heart sections with ApopTag® 
Fluorescein Apoptosis Detection Kit (Millipore, Billerica, MA, USA). Briefly, slides 








digested in a 1:50 dilution of proteinase K (Dako, Carpinteria, CA, USA) for 25 minutes, 
rinsed in TBS, and covered in equilibration buffer for 10 seconds. Tdt enzyme/buffer was 
added to each section and slides were incubated in a 37 °C oven for 2 hours. After 
stopping the reaction, slides were again rinsed in TBS and an anti-digoxigenin-
fluorescein conjugate was added for 1 hour at room temperature. After a final rinse in 
TBS and addition of immunofluorescent mounting media (Dako, Carpinteria, CA, USA), 
the cover slips were added to the slides. 
Immunohistochemistry and H&E stains were digitized by scanning the entire slide 
at 20× magnification using an Aperio CS Scanscope (Aperio Technologies, Inc., Vista, 
CA, USA). Immunohistochemical slides stained for BNIP3 were analyzed by manually 
counting BNIP3-positive nuclei from five random high power fields in each heart using 
Aperio ImageScope V11.2.0.780 (Aperio Technologies, Inc., Vista, CA, USA). 
TUNEL immunofluorescence slides were imaged at 40× magnification using an 
Olympus FV1000 confocal fluorescent microscope (Olympus, Center Valley, PA, USA) 
and quantified by counting positively stained cells from five random high power fields 
for each animal. 
5.3.7 Statistical Analysis 
All results are reported as the mean value ± standard error of the mean (SEM). 
Statistical analysis was performed in GraphPad Prism 4.03 (GraphPad Software, La Jolla, 
CA, USA) using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc 




5.4.1 Infarct Size and Collagen Content 
The left anterior descending coronary artery supplies blood to the anterior surface 
of the LV and the apex of the heart. Ligation of this coronary artery produces large, 
fibrotic LV infarcts that are readily detectable by collagen staining (Figure 5.1). 
Sectioned hearts from each treatment group were stained with the collagen-specific 
Masson’s Trichrome stain. The infarct area was measured as a percentage of the total 
cross-sectional area of the left ventricle at 14 days postinfarction (Figure 5.2a). As seen in 
Figure 5.2b–d, the siBNIP3:ABP-treated hearts showed a smaller area of infarction 
within the myocardial region supplied by the LAD compared to ischemia/reperfusion 
(I/R) control hearts. Quantitative assessment of all the hearts revealed that the 
siBNIP3:ABP treatment limited infarct formation to 8.29 ± 0.97% of the left ventricle. 
An average infarct size for the I/R controls was measured at 17.91 ± 1.80% and the 
infarcts for the siLuc:ABP nontargeting siRNA group and the naked siBNIP3 group 
measured 17.87 ± 1.83% and 16.46 ± 2.33%, respectively. The siBNIP3:ABP infarct size 
was statistically lower than all other groups at P < 0.01 versus I/R control and 
siLuc:ABP, and P < 0.05 versus naked BNIP3. 
5.4.2 Functional and Anatomical MRI Analysis 
To evaluate the effects of siRNA-mediated knockdown in vivo, we used a more 
physiologically relevant model of I/R in rats by ligating the LAD temporarily for 
30 minutes using a suture snare and then releasing the snare to commence the indefinite 
reperfusion period [34]. Before treatment, the animals were randomized to one of five 





Figure 5.1. Temporary ligation of the rat heart at the left anterior descending coronary 








Figure 5.2. Masson’s trichrome staining showing infarct formation between all treatment 
groups and I/R control. (a) Quantitative analysis of myocardial infarct size between all 
groups as a percent of the left ventricle. Representative Masson’s trichrome staining 
showing infarct formation in (b) ischemia/reperfusion only animals, (c) thoracotomy only 













































Figure 5.2 Continued. 
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siBNIP3 complexed with ABP (n = 7, 50 nM BNIP3 siRNA 1:20 w/w with ABP), I/R 
followed by injection of nontargeting siLuc complexed with ABP (n = 5, 50 nM Luc 
siRNA 1:20 w/w with ABP), and I/R followed by injection of 50 nM BNIP3 siRNA 
alone (n = 5). All treatment injections were delivered in 100 µl 1X PBS immediately after 
reperfusion. 
To determine the treatment effects on heart function and anatomy, we used 
cineMRI to evaluate the in vivo rat hearts 14 days after surgery. The first notable result 
was that treatment of infarcted rat hearts with siBNIP3:ABP led to significant 
preservation of heart ejection fraction 14 days after surgery (74.4 ± 4.4%). This ejection 
fraction value was reduced but not significantly lower than thoracotomy control animals 
(77.4 ± 3.1%), but was significantly higher than I/R controls (58.4 ± 3.9%, P < 0.05). The 
ejection fractions of the siLuc:ABP (64.4 ± 1.4%) and naked siBNIP3 (62.3 ± 1.9%) 
groups were lower than both thoracotomy and siBNIP3:ABP groups, but were not 
significantly increased compared to the I/R control group (Figure 5.3). 
In addition to the pumping efficiency indicator provided by the ejection fraction 
measurement, we also analyzed left ventricle volume at end diastole and end systole. The 
end diastolic volume (EDV) between all groups was not statistically different from either 
the I/R control group nor the thoracotomy control group, demonstrating that left 
ventricular remodeling had not yet progressed to the point where chamber dilation had 
occured. The mean EDV for siBNIP3:ABP-treated animals was 281 ± 15 µl while the 
EDV for I/R only and thoracotomy control animals was 309 ± 21 µl and 308 ± 17 µl, 





Figure 5.3. MRI analysis of rat hearts for functional analysis by ejection fraction. The 
























































Evaluation of left ventricle volume at end systole revealed that the I/R only 
animals experienced a large and significant increase in end systolic volume (ESV) 
compared to both thoracotomy controls and siBNIP3:ABP-treated animals. The I/R only 
treatment group ESV was measured at 109 ± 9 µl while thoracotomy animals measured 
71 ± 13 µl and siBNIP3:ABP animals measured 60 ± 6 µl (P < 0.05 I/R vs. thoracotomy, 
P < 0.01 vs. siBNIP3:ABP). The siLuc:ABP and naked siBNIP3 groups measured 
94 ± 4 µl and 88 ± 7 µl, respectively, and were not statistically lower than the negative 
I/R only control group (Figure 5.4b). 
5.4.3 Temporal Wall Thickening 
Left ventricle wall thickness was evaluated throughout the entire cardiac cycle (15 
individual time frames) at a midventricular level. The left ventricle was divided into 4 
sectors with each sector comprising 90° of the ventricle and sector 1 beginning at a line 
that bisects the short-axis of the heart, equally dividing the left and right ventricles. 
Sector 2 comprises the anterior surface of the left ventricle, which is the portion of the 
left ventricle that is primarily supplied by the LAD. Notably, the I/R rats demonstrated 
little change between all sectors between end diastole and end systole, which is reflected 
in the poor ejection fraction seen in these animals. Additionally, the left ventricle wall 
displayed essentially no thickening throughout the cardiac cycle within sector 2. 
Thoracotomy controls displayed a significant difference between all sectors from end 
diastole to end systole with no difference between the LAD sector (sector 2) and the other 
sectors of the left ventricle. Finally, the siBNIP3:ABP group also showed a large change 
in wall thickness between all sectors from end diastole to end systole with no discernible 














Figure 5.4. MRI analysis of rat hearts for global changes in end diastolic and end systolic 
left ventricle chamber volumes. (a) End diastolic volume for all treatment groups, (b) end 


























































































































Figure 5.5. Temporal wall thickening for I/R only (top), thoracotomy (middle), and 
siBNIP3:ABP (bottom). 
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5.4.4 Cardiomyocyte Hypertrophy and Density 
To evaluate the degree of remodeling, we analyzed cardiomyocyte cross-sectional 
surface area, and cardiomyocyte density. The cross-sectional area of cardiomyocytes in 
I/R only hearts was almost 3-times larger than the area of cardiomyocytes in thoracotomy 
control hearts (796.7 ± 58.3 µm
2
 vs. 267.8 ± 18.3 µm
2
, respectively, P < 0.001). 
siBNIP3:ABP hearts showed a significantly decreased cross-sectional area at 
413.3 ± 32.6 µm
2
 versus I/R hearts (P < 0.001). siLuc:ABP and naked siBNIP3 controls 
showed a similar degree of hypertrophy as I/R only controls (691.5 ± 60.6 µm
2
 and 
727.6 ± 62.9 µm
2
) (Figure 5.6a). 
In agreement with the hypertrophy data, cardiomyocyte density was significantly 
decreased from thoracotomy controls in I/R only hearts (1,100 ± 58 cells/mm
2
 I/R vs. 
1,920 ± 103 cells/mm
2
 thoracotomy, P < 0.001). Density of cardiomyocytes in 
siBNIP3:ABP-treated hearts (1,590 ± 91.2 cells/mm
2
) was slightly decreased from 
thoracotomy controls (P < 0.05) but significantly elevated over I/R only hearts 
(P < 0.001). The density of cardiomyocytes in siLuc:ABP hearts at 
1,210 ± 43.3 cells/mm
2
 and in naked siBNIP3 hearts at 1,250 ± 47.7 cells/mm
2
 was 
slightly decreased from siBNIP3:ABP hearts (P < 0.05) but were not significantly 
increased over I/R only controls (Figure 5.6b). 
Figures 5.6c–d contain representative micrographs showing differences in 
cardiomyocyte density, and myocyte cross-section between I/R only, thoracotomy, and 
siBNIP3:ABP-treated rat hearts. The large increase in cardiomyocyte cross-section is 














Figure 5.6. Cardiomyocyte hypertrophy and density from H&E staining. (a) 
Cardiomyocyte cross-sectional area in µm
2
. (b) Cardiomyocyte density in cells/mm
2
. 
Representative micrographs of (c) I/R only control animals, (d) thoracotomy controls, 






























































































































Figure 5.6 Continued. 
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5.4.5 BNIP3 Immunohistochemistry 
Immunohistochemical analysis of the rat hearts revealed that there were a 
significant number of BNIP3-positive cells in the I/R only heart group, whereas there 
were very few positive cells in the thoracotomy control group or the siBNIP3:ABP 
treatment group (Figure 5.7). 
5.4.6 TUNEL Immunofluorescence 
Finally, to evaluate the degree of apoptosis/necrosis in the myocardium, an 
immunofluorescent TUNEL assay was performed on all samples. The left ventricles of 
all animals were analyzed for TUNEL-positive nuclei at 40× magnification in 5 random 
high power fields per animal. Analysis of thoracotomy surgery control animals revealed 
that the assay identified 69.4 ± 6.7 positive nuclei/mm
2
 as a background level of 
apoptosis (Figure 5.8). I/R only rats had a significantly increased number of TUNEL-
positive cells at 225.4 ± 14.7 cells/mm
2
 (P < 0.001). Treatment siBNIP3:ABP hearts 
showed a significant decrease in apoptotic cells, but did not quite have as few positive 
cells as thoracotomy hearts (95.9 ± 8.1 cells/mm
2
, P < 0.001 vs. I/R only, NS vs. 
thoracotomy). Naked BNIP3-treated hearts and siLuc:ABP hearts were increased to the 
same levels as I/R control animals and were significantly increased over both 
siBNIP3:ABP and thoracotomy hearts, but were not significantly different from I/R only 
control heart levels (264.2 ± 14.5 cells/mm
2
 and 234.3 ± 22.6 cells/mm
2
, respectively, 
P < 0.001 vs. both siBNIP3:ABP and thoracotomy, NS vs. I/R only).  
5.5 Discussion 
Considering the high incidence of acute myocardial infarction and the lack of 





Figure 5.7. BNIP3 immunohistochemical staining showing increased BNIP3 expression 
in I/R only hearts (a), but with no detectable BNIP3 expression in thoracotomy (b), and 




























































the exploration of new treatment strategies such as gene therapy is of extreme 
importance. Our work investigated the effects of bioreducible polymer-delivered BNIP3 
siRNA to test the hypothesis that limiting BNIP3-mediated apoptosis in the early phase 
immediately after MI can result in decreased ventricular remodeling with preservation of 
heart function. 
In previous studies performed by our group, we have shown that polymer-
mediated VEGF gene therapy can be used to promote angiogenesis, reducing left 
ventricular remodeling and improving heart function [12, 35-37]. Angiogenic approaches, 
while popular, are limited in their ability to repopulate the myocardium and are better 
suited to retaining populations of cells that survived the initial I/R injury but are located 
in at-risk infarct border zones. Cell therapies have been extensively studied in both 
research and clinical settings and are designed to implant populations of cells that can 
hopefully either differentiate to cardiomyocytes or exert a positive influence on the 
remaining myocardial cells via paracrine effects [38-40]. This technique has seen success 
in some human trials, but the approach is still limited by questions as to whether the 
implanted cells are truly repopulating the myocardium with electromechanically 
competent and synchronously contracting myocytes [41-43]. An approach that focuses on 
retaining endogenous cardiomyocytes is attractive as it could circumvent many of the 
problems experienced with cell therapies by preserving the functional endogenous 
population of cardiomyocytes and support cells. 
Our lab has investigated and demonstrated the feasibility of using polymer-
mediated siRNA gene inhibition to limit apoptosis in cardiomyocytes in vitro; however, 
this work had not been expanded to in vivo animal models [44-46]. In this work, we 
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wanted to investigate not only the utility of transient siRNA-mediated inhibition of a 
proapoptotic gene to prevent cardiomyocyte death, but to demonstrate proof-of-principle 
that BNIP3 is an apropriate target for gene therapy of the myocardium post-MI. 
Studies have shown that ventricular remodeling is progressive in nature with the 
extent of injury early after acute ischemic insult correlating to the size of the infarct and 
the degree of remodeling [47, 48]. The early stage is characterized by rapid metabolic 
changes, causing oxidative stress on cardiomyocytes and resulting in increased levels of 
apoptosis, necrosis, and autophagy in the myocardium [49, 50]. Annexin V staining in 
human patients suffering acute MI has indicated that the level of apoptosis decreases after 
the first week in the myocardial area-at-risk while TUNEL assays on autopsied hearts 
showed peak apoptosis within 3 days [50, 51]. This early loss of endogenous cells is 
thought to play an important role in determining the degree of LV remodeling and loss of 
heart function and suggests that there is a window of opportunity to gain long-term 
benefits by protecting cells from apoptosis in the early stage following acute MI. The 
short duration of siRNA therapy limits its utility for treating diseases in organs such as 
the heart that are difficult to access locally. However, with evidence suggesting that the 
myocardium is at increased risk for death over a shorter 1-week window, this creates an 
opportunity to see long-term benefit from siRNA therapy over a short duration. 
The animal results we observed are particularly promising, showing that the 
knockdown of BNIP3 locally in the infarcted rat heart can produce positive global and 
regional functionality and demonstrate morphological improvement in LV remodeling 
progression. Globally, the treatment groups demonstrated preserved heart function as 
measured by ejection fraction. Ejection fraction is an important measure of heart function 
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both in animal models and in human patients, providing important prognostic information 
regarding the long-term expectations for the patient [47]. While we did not identify any 
statistical difference in end diastolic volume between any of the treatment groups, this is 
possibly due to the short 2-week study length, and the use of a less severe 30-minute 
occlusion/reperfusion protocol to induce infarction in the animals. Over this time period, 
remodeling in the LV may not have progressed to the point where wall thinning and 
cardiomyocyte slipping led to increased diastolic chamber volumes. However, we did see 
a significant impact on end systolic function within the hearts of I/R only control animals, 
siLuc:ABP nontargeting control, and naked BNIP3 delivery control animals. This is 
especially important since systolic function is an important determinant for long-term 
survival [47].  
The regional results from the temporal wall-thickening measurements shed some 
insight into the reasons for loss of efficient systolic emptying of the LV. The I/R only 
animals showed significant loss of cardiomyocyte function in the LV region supplied by 
the experimentally ligated LAD. Over the course of a heart cycle, I/R only (and 
siLuc:ABP, and naked BNIP3) animals showed very little thickening of the myocardial 
wall in the infarct zone. This demonstrates that whether due to loss of cardiomyocytes, 
increased fibrosis, or cardiomyocyte dysfunction, the region of the heart where the infarct 
occurs was dramatically less functional than the unaffected regions. Conversely, 
treatment with siBNIP3:ABP demonstrated that it has a positive effect on the infarct zone 
with no significant difference in end diastolic to end systolic wall thickening detected. 
Morphological analysis of all animal groups revealed that LV cellular remodeling 
in the form of increased cardiomyocyte hypertrophy was occurring in I/R only and 
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control groups, but was prevented in the siBNIP3:ABP group. In Figure 5.6e of the 
siBNIP3:ABP group, we can see that the cross-sectional area of the cardiomyocytes is 
significantly less than that seen in Figure 5.6c of the I/R only animals, despite the evident 
fibrosis in each of the panels. 
Finally, our results show that as a result of our reduction in BNIP3 mRNA levels 
in the acute early phase of MI, we were still able to detect significantly lower levels of 
apoptosis after 2 weeks. This demonstrates that, as shown in long-term knockout and 
deletion models reported in the literature, BNIP3 removal or reduction leads to decreased 
levels of apoptosis/necrosis in the myocardium. Even more interestingly, this 
demonstrates that after MI, the myocardium does pass through a stage of increased 
apoptosis and that prevention of apoptosis during this short period can translate to long-
term decreases in cell death. Normally, siRNA administration results in peak target 
knockdown between 24–48 hours with a total duration of less than 1 week. The duration 
of this effect can depend on factors such as target mRNA expression levels and cellular 
turnover. 
This study and others have identified BNIP3 as a particularly attractive target for 
prevention of myocardial apoptosis/necrosis post-MI for myriad reasons. First, the role of 
BNIP3 as a hypoxia-responsive mediator of cardiomyocyte cell death has been well-
established in both in vitro and in vivo models [29, 52, 53]. Also, transgenic studies show 
that BNIP3 deletion improves heart function and decreases LV remodeling  [29], while in 
vitro studies in cardiac myocytes demonstrated that cell death is blocked by BNIP3 
antisense oligonucleotides [54]. Our work shows similar protection from left ventricular 
remodeling, decreased infarct formation, and cell death as has been noted in permanent 
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BNIP3 knockout studies, but is a more practical approach that could be used as therapy 
post-MI. 
5.6 Conclusions 
In conclusion, this work demonstrated that the inhibition of BNIP3 as an 
antiapoptotic target serves to protect mammalian cardiomyocytes from hypoxia- and 
reperfusion-related injuries in vivo. This demonstrates BNIP3 is a novel target for the 
treatment of myocardial infarction and the prevention of left ventricular remodeling after 
heart attack. While this study examined inhibition of BNIP3 using polymer-delivered 
siRNA and suggest that polymer-mediated siRNA therapy could be a feasible therapeutic 
approach, the principles can be broadly expanded with potential applications for small 
molecules targeting BNIP3. Additionally, we were able to show that the novel arginine-
grafted bioreducible polymer ABP can produce efficient siRNA transfection locally to 
hearts in vivo with no observed side effects or toxicity. 
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Overall, the work in this dissertation demonstrates that disulfide-linked 
bioreducible polymers can be used to promote therapeutic gene delivery to address the 
deleterious effects of myocardial infarction. The therapeutic potential of gene therapy as 
an alternative and superior approach to treating many diseases remains to be met largely 
due to technical issues surrounding implementation of prolonged gene transduction in 
target cells. The failure of gene therapy to meet its clinical potential to date is principally 
due to difficulties in designing efficient gene vectors with acceptable safety profiles. We 
have demonstrated that polymeric systems, particularly bioreducible ones, represent a 
viable approach to effecting gene transfer with minimal side effects and high efficacy. 
In Chapter 3, we observed that VEGF-transfected skeletal myoblasts stably 
express VEGF165 and promote angiogenesis when implanted into the rat heart after 
permanent acute myocardial infarction. The polymer poly(CBA-DAH) was able to 
transfect the skeletal myoblasts and produce high transgene expression without 
significant toxicity. The implanted cells induced neovascularization of the myocardium 
as determined by CD31 and SMA immunohistochemistry, with notable increased vessel 
and capillary formation compared to controls. Also, ejection fraction, a clinically 
important measurement of heart function, was greatly increased in the VEGF-transfected 
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treatment group, demonstrating that the angiogenic effect of the transfected cell 
implantation results in retention of healthy heart function. Also, LV remodeling 
progressed significantly less in the rats treated with VEGF-transfected myoblasts, 
showing that this treatment strategy can slow the progression of global and regional 
remodeling of the LV wall and chamber. Finally, infarct size and apoptosis levels were 
dramatically decreased in the VEGF/myoblast treatment group, showing that the 
angiogenic therapy can promote cell survival, resulting in more viable myocardium. 
Chapter 4 demonstrated that the cardiomyocyte transfection efficiency of the 
poly(CBA-DAH) bioreducible polymer can be improved through conjugation of 
nitrogen-rich arginine groups to form poly(CBA-DAH-R), an arginine-conjugated 
bioreducible polymer (ABP). This polymer showed minimal toxicity to primary 
cardiomyocytes while producing high transgene expression, suggesting its potential 
utility for in vivo use. Additionally, this chapter set the initial validation work of the 
hypoxia-inducible death switch BNIP3, demonstrating that siRNA towards BNIP3 can 
produce significant knockdown at both mRNA and protein levels. Finally, using an in 
vitro hypoxia model, we observed that BNIP3 inhibition via ABP-delivered siRNA 




 chapter expanded on the in vitro work performed in the previous chapter, 
evaluating the therapeutic benefit of polymer-delivered BNIP3 siRNA. A rat 
ischemia/reperfusion model of MI was used and siBNIP3 polyplexes were delivered 
directly to the myocardial infarct and border zone to reduce acute cell death. This 
approach not only produced regional improvements in the infarct region as demonstrated 
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by the reduced infarct sizes, but this improvement translated to improved heart function 
compared to control animals. Overall improvement in markers of LV remodeling such as 
cardiomyocyte density and hypertrophy showed that siBNIP3 therapy limits remodeling 
of the myocardium on a cellular level. The retention of systolic chamber volumes also 
demonstrated that LV remodeling is also improved on a global ventricular level also. 
Finally, the TUNEL analysis showed that apoptotic and necrotic cell populations 2 weeks 
after MI were reduced over 2-fold compared to control groups and were almost reduced 
to preinjury levels. 
In summary, the work in this dissertation demonstrates that gene therapy 
approaches using nontoxic bioreducible polymers to treat MI and prevent LV remodeling 
are possible and of potential clinical value. This work evaluated two very different 
mechanisms of myocardial protection and demonstrated that while both approaches have 
their limitations, they can also be very effective in preventing pathological remodeling. 
6.2 Limitations 
Since this dissertation relies heavily on in vivo animal models of MI to identify 
novel therapeutic strategies to treat the disease, it is important to consider some of the 
limitations in translating positive animal results to meaningful clinical therapies. Over the 
past years, it has been found that many therapies that have shown excellent results in 
animal disease models, especially those models of cardiovascular disease, have failed to 
translate these research successes to the clinic [1]. 
These limitations are due to a variety of factors and basic limitations that come 
from controlling variables in lab experiments that cannot be controlled in the real world. 
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Some of the major differences between animal and clinical studies on MI and possible 
means to increase translatability are examined below. 
In animal models of MI, the animals come from a homogenous group of healthy, 
usually young population and are also normally free of comorbidities. In human patients 
presenting with acute MI, the population is very heterogeneous, middle-aged or older, 
and often present with additional comorbidities such as hypertension, dyslipidemia, and 
diabetes. Many of these diseases are known to exacerbate conditions such as MI. To 
address these issues, researchers should look at using older populations of animals with 
comorbidities.  
In animal models, only drugs that are involved in the therapy or that are medically 
necessary to perform the procedure are given. In humans, patients who present with MI 
are normally taking more than one medication, which can influence the impact of the 
therapy being studied. This is a difficult condition to control in humans, but proper 
recording and tracking of drugs currently being taken by patients will allow the 
researcher to determine potential influencing roles of classes of medication over time. 
The duration of the ischemic period in animals is usually short (30–60 minutes) 
and all animals receive the same duration of ischemia throughout the study. In humans, 
the duration of ischemia is much longer with time-to-reperfusion ranging from 3 to over 
12 hours in some patients due to variability in transport time, physician, and facility 
availability. Also, within a study, the range of ischemic durations can be highly variable, 
making direct comparisons difficult. This can be addressed by introducing larger 
variation and ischemic times in animal studies while in human studies, the subjects 
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should be analyzed and compared within windows of treatment such as <4 hours or 
between 4–8 hours. 
Most animal studies produce an acute mechanical occlusion on the same healthy 
coronary vessel and at the same site. In humans, the location of the occlusion, the vessel 
patency, and the health of the coronary artery are all highly variable, making direct 
comparisons more challenging. Spontaneous atherosclerotic animal models exist and may 
make better approximations of MI in humans. 
Therapeutic intervention in animal models is often timed to occur at the time of 
reperfusion or ischemia. This is often due to limitations of laboratory research as it is 
much simpler and more convenient to make interventions at the time of the surgery. This 
is especially a limitation in strategies that employ direct intervention with the 
myocardium as it is difficult and cumbersome to perform separate interventional 
surgeries in lab animals. In humans, as mentioned above, there is high variability in the 
time to intervention. Care should be taken to consider the timing of the therapy in clinical 
trials. 
Infarcts in animal models of myocardial infarction are often much larger than 
those seen in human patients. Depending on the model of MI used, infarcts of between 25 
to over 50% are often seen in animals. Human infarct size is typically much smaller, with 
infarcts from 10–20% of the LV more common. Newer animal models such as the 
30-minute ischemia/reperfusion model used in Chapter 4 of this dissertation produce 
more modest infarcts and may be a more reliable comparator for human studies. 
Finally, most animal studies are performed over a short period of time with 
average times ranging from 2–6 weeks for studies evaluating LV remodeling. Also, the 
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most common endpoints used in laboratory studies are cardiac function and geometry, 
and infarct size. These endpoints are not as clinically significant as evaluating the long-
term effects of an intervention of health measurements such as subsequent animal illness 
and death. Longitudinal animal studies may be more clinically relevant and directly 
translatable to the impact of an intervention in human application. 
Overall, the shortcomings of animal studies and their lack of translatability to 
human therapy are understandable when the differences between the experimental 
strategies are more closely examined. However, it is impractical to expect that all animal 
studies be performed with the degree of variability and rigor necessary to more closely 
model human disease. The researcher should at least have an understanding of some of 
these constraints so that the limitations of his or her findings can be appreciated and so 
that advanced studies can be planned to eliminate some of the shortcomings of realistic 
laboratory animal models. 
6.3 Future Directions 
6.3.1 Dual Plasmid for Mature Angiogenesis 
As mentioned earlier, VEGF is the most common angiogenic factor used for 
therapeutic angiogenesis [2]. However, it has also been well established that while VEGF 
is the most potent factor to promote rapid neoangiogenesis, the vessels it stimulates are 
immature, leaky, and do not last much longer after VEGF levels return to baseline [3, 4]. 
To increase the functionality of the new vasculature, a dual-gene therapy approach 
combining the rapid VEGF factor with a vascular maturing factor such as PDGF should 
rapidly induce new vasculature growth while promoting vessel maturation for long-term 
benefit even after VEGF levels have abated [5]. 
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6.3.2 Combined Antiapoptosis and Angiogenesis Treatment Modality 
The chapters in this dissertation investigate two therapeutic modalities for the 
treatment of acute MI and prevention of LV remodeling: therapeutic angiogenesis and 
myocardial antiapoptosis. As highlighted in Figure 1.1, these two treatment strategies 
show maximal benefit at distinct windows after the initial ischemic insult. Therapeutic 
angiogenesis typically occurs outside the early phase of acute MI and serves to assist in 
rebuilding a functional vascular system to supply the myocardium with oxygen and 
nutrients. Antiapoptotic strategies have the potential to produce maximal benefit when 
implemented immediately after the initial ischemic phase, as this is the period of highest 
cardiomyocyte death [6, 7]. By devising a strategy combining fast-acting antiapoptotic 
siRNA and long-term pDNA-mediated angiogenesis, the benefits of both strategies could 
combine synergistically to produce a therapeutic effect greater than either intervention 
alone. Our lab is currently pursuing this strategy and has performed initial in vitro studies 
using an anti-SHP-1 (Src homology domain 2 (SH2)-containing tyrosine phosphatase-1) 
siRNA sequence combined with a hypoxia-inducible VEGF-expressing plasmid. Both the 
SHP-1 siRNA and hypoxia-inducible VEGF strategies have been evaluated in vitro in our 
lab but have not yet been combined in an in vivo animal model [8-12]. 
6.3.3 Local Heart Targeting via Systemic Delivery 
The delivery approaches in this dissertation relied on local injection directly into 
the myocardium. Local injection at the time of insult is the most widely used technique in 
research due largely to its simplicity, the effectiveness of local injection, and the 
difficulty involved in re-accessing the site to deliver the therapy at a later time or date. 
However, this approach does not accurately replicate the therapeutic strategy likely to be 
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employed in a clinical setting. In human patients, local injection is possible but is limited 
to: 1) injection through the chest wall, which is difficult to perform accurately; 2) 
injection via catheter based systems, which again can be difficult and presents risks of 
complication during the procedure; and 3) injection at the time of thoracic surgery, which 
is the most accurate technique but only a small number of patients may actually have 
indications for cardiothoracic surgery. Development of systems that allow targeted 
delivery of genes to the ischemic myocardium are a preferable approach as these systems 
would allow for multiple dosing schedules through simple intravenous injection. 
Our lab has been working on approaches to develop targeted bioreducible cationic 
polymers to target polyplexes to the ischemic myocardium. We have conjugated a short 
nine-residue targeting polypeptide, identified by in vivo phage display and capable of 
homing to ischemic myocardium [13], to a bioreducible polymer and demonstrated that it 
can selectively target the polyplex to the ischemic portion of the heart immediately after 
MI. Additional work with this targeted polymer gene delivery system is still needed to 
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